

Prescription and Over-the-Counter Drug Product List

42ND EDITION

Cumulative Supplement Number 01 : January 2022

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

| | | | | | | | | | |
|-----|--|---------------------------------|---------|---------|--------------|--------------|------|------|--|
| >A> | <u>ABROCITINIB</u> | | | | | | | | |
| >A> | TABLET;ORAL | | | | | | | | |
| >A> | CIBINQO | | | | | | | | |
| >A> | + PFIZER | 50MG | | N213871 | 001 | Jan 14, 2022 | Jan | NEWA | |
| >A> | + | 100MG | | N213871 | 002 | Jan 14, 2022 | Jan | NEWA | |
| >A> | + | 200MG | | N213871 | 003 | Jan 14, 2022 | Jan | NEWA | |
| | <u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u> | | | | | | | | |
| | CAPSULE;ORAL | | | | | | | | |
| | BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE | | | | | | | | |
| >A> | AB HIKMA | 300MG;50MG;40MG;30MG | | A215138 | 002 | Jan 26, 2022 | Jan | NEWA | |
| >A> | AB | 325MG;50MG;40MG;30MG | | A215138 | 001 | Jan 26, 2022 | Jan | NEWA | |
| >D> | LGM PHARMA | 300MG;50MG;40MG;30MG | | A076560 | 002 | Jul 19, 2012 | Jan | CTEC | |
| >A> | AB | 300MG;50MG;40MG;30MG | | A076560 | 002 | Jul 19, 2012 | Jan | CTEC | |
| | <u>ACETYLCYSTEINE</u> | | | | | | | | |
| | INJECTABLE;INTRAVENOUS | | | | | | | | |
| | ACETYLCYSTEINE | | | | | | | | |
| >A> | AP ASPEN | 6GM/30ML (200MG/ML) | | A213693 | 001 | Feb 03, 2022 | Jan | NEWA | |
| | <u>ALLOPURINOL</u> | | | | | | | | |
| | INJECTABLE;INJECTION | | | | | | | | |
| | ALLOPURINOL | | | | | | | | |
| >A> | AP GLAND PHARMA LTD | EQ 500MG BASE/VIAL | | A212363 | 001 | Jan 26, 2022 | Jan | NEWA | |
| | <u>AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE</u> | | | | | | | | |
| | TABLET;ORAL | | | | | | | | |
| | CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE | | | | | | | | |
| >A> | AB MICRO LABS | EQ 12.5MG BASE;5MG | | A211925 | 001 | Feb 02, 2022 | Jan | NEWA | |
| >A> | AB | EQ 25MG BASE;10MG | | A211925 | 002 | Feb 02, 2022 | Jan | NEWA | |
| >D> | MYLAN PHARMS INC | EQ 12.5MG BASE;5MG | | A071297 | 002 | Dec 10, 1986 | Jan | CTEC | |
| >A> | AB | EQ 12.5MG BASE;5MG | | A071297 | 002 | Dec 10, 1986 | Jan | CTEC | |
| >D> | ! | EQ 25MG BASE;10MG | | A071297 | 001 | Dec 10, 1986 | Jan | CTEC | |
| >A> | AB ! | EQ 25MG BASE;10MG | | A071297 | 001 | Dec 10, 1986 | Jan | CTEC | |
| | <u>AMLODIPINE BESYLATE</u> | | | | | | | | |
| | TABLET;ORAL | | | | | | | | |
| | AMLODIPINE BESYLATE | | | | | | | | |
| >A> | @ CHARTWELL RX | EQ 2.5MG BASE | | A076859 | 001 | Sep 10, 2007 | Jan | CAHN | |
| >A> | @ | EQ 5MG BASE | | A076859 | 002 | Sep 10, 2007 | Jan | CAHN | |
| >A> | @ | EQ 10MG BASE | | A076859 | 003 | Sep 10, 2007 | Jan | CAHN | |
| >D> | @ YAOPHARMA CO LTD | EQ 2.5MG BASE | | A076859 | 001 | Sep 10, 2007 | Jan | CAHN | |
| >D> | @ | EQ 5MG BASE | | A076859 | 002 | Sep 10, 2007 | Jan | CAHN | |
| >D> | @ | EQ 10MG BASE | | A076859 | 003 | Sep 10, 2007 | Jan | CAHN | |
| | NORVASC | | | | | | | | |
| >D> | AB + UPJOHN | EQ 2.5MG BASE | | N019787 | 001 | Jul 31, 1992 | Jan | CAHN | |
| >D> | AB + | EQ 5MG BASE | | N019787 | 002 | Jul 31, 1992 | Jan | CAHN | |
| >D> | AB +! | EQ 10MG BASE | | N019787 | 003 | Jul 31, 1992 | Jan | CAHN | |
| >A> | AB + VIATRIS | EQ 2.5MG BASE | | N019787 | 001 | Jul 31, 1992 | Jan | CAHN | |
| >A> | AB + | EQ 5MG BASE | | N019787 | 002 | Jul 31, 1992 | Jan | CAHN | |
| >A> | AB +! | EQ 10MG BASE | | N019787 | 003 | Jul 31, 1992 | Jan | CAHN | |
| | <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE</u> | | | | | | | | |
| | CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | | |
| | DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE | | | | | | | | |
| >A> | AB TEVA PHARMS USA | 3.125MG;3.125MG;3.125MG;3.125MG | A210876 | 001 | Jan 31, 2022 | Jan | NEWA | | |
| >A> | AB | 6.25MG;6.25MG;6.25MG;6.25MG | A210876 | 002 | Jan 31, 2022 | Jan | NEWA | | |
| >A> | AB | 9.375MG;9.375MG;9.375MG;9.375MG | A210876 | 003 | Jan 31, 2022 | Jan | NEWA | | |
| >A> | AB | 12.5MG;12.5MG;12.5MG;12.5MG | A210876 | 004 | Jan 31, 2022 | Jan | NEWA | | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

APREMILAST

TABLET; ORAL

APREMILAST

| | | | | | | | | |
|-----|----|--------|------|---------|-----|--------------|-----|------|
| >D> | AB | AMNEAL | 10MG | A211782 | 001 | Jun 30, 2021 | Jan | DISC |
| >A> | | @ | 10MG | A211782 | 001 | Jun 30, 2021 | Jan | DISC |
| >D> | AB | | 20MG | A211782 | 002 | Jun 30, 2021 | Jan | DISC |
| >A> | | @ | 20MG | A211782 | 002 | Jun 30, 2021 | Jan | DISC |
| >D> | AB | | 30MG | A211782 | 003 | Jun 30, 2021 | Jan | DISC |
| >A> | | @ | 30MG | A211782 | 003 | Jun 30, 2021 | Jan | DISC |

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

| | | | | | | | | |
|-----|----|-------|---------------------|---------|-----|--------------|-----|------|
| >A> | AN | LUPIN | EQ 0.015MG BASE/2ML | A213068 | 001 | Feb 07, 2022 | Jan | NEWA |
|-----|----|-------|---------------------|---------|-----|--------------|-----|------|

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; INTRAVENOUS

M.V.I. PEDIATRIC

| | | | | | | | | |
|-----|---|---|---------|--|-----|--------------|-----|------|
| >D> | | | | | | | | |
| >D> | + | ! | HOSPIRA | 80MG/VIAL;0.02MG/VIAL;0.001MG/V N018920 | 001 | Sep 21, 2000 | Jan | DISC |
| | | | | IAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL | | | | |
| >A> | + | | @ | 80MG/VIAL;0.02MG/VIAL;0.001MG/V N018920 | 001 | Sep 21, 2000 | Jan | DISC |
| | | | | IAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL | | | | |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS

M.V.I. ADULT

| | | | | | | | | |
|-----|---|---|---------|--|-----|--------------|-----|------|
| >D> | | | | | | | | |
| >D> | + | ! | HOSPIRA | 200MG/VIAL;0.06MG/VIAL;0.005MG/ N021625 | 001 | Jan 30, 2004 | Jan | DISC |
| | | | | VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL | | | | |
| >A> | + | | @ | 200MG/VIAL;0.06MG/VIAL;0.005MG/ N021625 | 001 | Jan 30, 2004 | Jan | DISC |
| | | | | VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL | | | | |
| >D> | | | | M.V.I. ADULT (PHARMACY BULK PACKAGE) | | | | |
| >D> | + | ! | HOSPIRA | 200MG/5ML;0.06MG/5ML;0.005MG/5M N021643 | 001 | Feb 18, 2004 | Jan | DISC |
| | | | | L;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML | | | | |
| >A> | + | | @ | 200MG/5ML;0.06MG/5ML;0.005MG/5M N021643 | 001 | Feb 18, 2004 | Jan | DISC |
| | | | | L;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML | | | | |

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

| | | | | | | | | |
|-----|----|------------------|----------------------|---------|-----|--------------|-----|------|
| >D> | AB | MAYNE PHARMA INC | 325MG;50MG;40MG;30MG | A203335 | 001 | Oct 30, 2015 | Jan | DISC |
| >A> | | @ | 325MG;50MG;40MG;30MG | A203335 | 001 | Oct 30, 2015 | Jan | DISC |

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

| | | | | | | | | |
|-----|----|---------------------|---------------|---------|-----|--------------|-----|------|
| >A> | AB | HETERO LABS LTD III | EQ 150MG BASE | A212278 | 001 | Feb 02, 2022 | Jan | NEWA |
| >A> | AB | | EQ 200MG BASE | A212278 | 002 | Feb 02, 2022 | Jan | NEWA |
| >A> | AB | | EQ 300MG BASE | A212278 | 003 | Feb 02, 2022 | Jan | NEWA |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

| | | | | | | | | |
|-----|----|-------------|----------------------|---------|-----|--------------|-----|------|
| >A> | AP | AMNEAL | 0.5MG/5ML (0.1MG/ML) | A215342 | 001 | Jan 26, 2022 | Jan | NEWA |
| >D> | | + @ HOSPIRA | 0.5MG/5ML (0.1MG/ML) | N021146 | 001 | Jul 09, 2001 | Jan | CMFD |
| >A> | AP | + | 0.5MG/5ML (0.1MG/ML) | N021146 | 001 | Jul 09, 2001 | Jan | CMFD |

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

| | | | | | | | | |
|-----|----|------------------|----------------|---------|-----|--------------|-----|------|
| >D> | AA | MAYNE PHARMA INC | 0.025MG; 2.5MG | A210789 | 001 | Jun 03, 2020 | Jan | DISC |
| >A> | | @ | 0.025MG; 2.5MG | A210789 | 001 | Jun 03, 2020 | Jan | DISC |

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

| | | | | | | | | |
|-----|--|-------------------|------------------------|---------|-----|--------------|-----|------|
| >D> | | +! MERIDIAN MEDCL | 2.1MG/0.7ML; 600MG/2ML | N021983 | 001 | Sep 28, 2006 | Jan | CAHN |
| >A> | | +! MMT | 2.1MG/0.7ML; 600MG/2ML | N021983 | 001 | Sep 28, 2006 | Jan | CAHN |

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

| | | | | | | | | |
|-----|----|--------|------------|---------|-----|--------------|-----|------|
| >A> | AP | AMNEAL | 100MG/VIAL | A211549 | 001 | Feb 03, 2022 | Jan | NEWA |
|-----|----|--------|------------|---------|-----|--------------|-----|------|

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------|----------------|---------|-----|--------------|-----|------|
| >D> | AB | AMNEAL | 0.2055MG/SPRAY | A208199 | 001 | Dec 15, 2017 | Jan | DISC |
| >A> | | @ | 0.2055MG/SPRAY | A208199 | 001 | Dec 15, 2017 | Jan | DISC |

BACLOFEN

TABLET; ORAL

BACLOFEN

| | | | | | | | | |
|-----|----|----------------|------|---------|-----|--------------|-----|------|
| >A> | AB | MANKIND PHARMA | 5MG | A215885 | 001 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | 10MG | A215885 | 002 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | 20MG | A215885 | 003 | Jan 25, 2022 | Jan | NEWA |

BENZONATATE

CAPSULE; ORAL

BENZONATATE

| | | | | | | | | |
|-----|----|------------------------|-------|---------|-----|--------------|-----|------|
| >A> | AA | ACELLA | 100MG | A091310 | 001 | Jan 16, 2015 | Jan | CAHN |
| >A> | AA | | 200MG | A091310 | 002 | Jan 16, 2015 | Jan | CAHN |
| >D> | AA | APOTEX INC | 100MG | A091310 | 001 | Jan 16, 2015 | Jan | CAHN |
| >D> | AA | | 200MG | A091310 | 002 | Jan 16, 2015 | Jan | CAHN |
| >A> | AA | ! THEPHARMANETWORK LLC | 100MG | A040627 | 002 | Mar 30, 2007 | Jan | CMS1 |
| >A> | AA | ! | 150MG | A040627 | 003 | Sep 24, 2014 | Jan | CMS1 |

>D> BENZOYL PEROXIDE; TRETINOIN

>D> CREAM; TOPICAL

>D> TWYNEO

| | | | | | | | | |
|-----|--|-------------------------|----------|---------|-----|--------------|-----|------|
| >D> | | +! SOL-GEL TECHNOLOGIES | 3%; 0.1% | N214902 | 001 | Jul 26, 2021 | Jan | DISC |
| >A> | | + @ | 3%; 0.1% | N214902 | 001 | Jul 26, 2021 | Jan | DISC |

BETAINE

FOR SOLUTION; ORAL

BETAINE

| | | | | | | | | |
|-----|----|--------------------|--------------|---------|-----|--------------|-----|------|
| >A> | AB | LUKARE MEDICAL LLC | 1GM/SCOOPFUL | A210508 | 001 | Jan 28, 2022 | Jan | NEWA |
|-----|----|--------------------|--------------|---------|-----|--------------|-----|------|

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|-----|----|---------------------|---------------|---------|-----|--------------|-----|------|
| >A> | AB | GLENMARK PHARMS LTD | 2.5MG; 6.25MG | A215995 | 001 | Jan 26, 2022 | Jan | NEWA |
| >A> | AB | | 5MG; 6.25MG | A215995 | 002 | Jan 26, 2022 | Jan | NEWA |
| >A> | AB | | 10MG; 6.25MG | A215995 | 003 | Jan 26, 2022 | Jan | NEWA |

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

| | | | | | | | | |
|-----|----|--------|-------|---------|-----|--------------|-----|------|
| >A> | AT | APOTEX | 0.15% | A078479 | 001 | Jan 31, 2022 | Jan | NEWA |
|-----|----|--------|-------|---------|-----|--------------|-----|------|

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

BUDESONIDE

CAPSULE, DELAYED RELEASE; ORAL

BUDESONIDE

| | | | | | | | | |
|-----|---|---------|-----|---------|-----|--------------|-----|------|
| >D> | @ | ALVOGEN | 3MG | A206724 | 001 | Nov 23, 2016 | Jan | CAHN |
| >A> | @ | NATCO | 3MG | A206724 | 001 | Nov 23, 2016 | Jan | CAHN |

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

| | | | | | | | | | |
|-----|----|---|------|-----------------|---------|-----|--------------|-----|------|
| >D> | AB | + | BDSI | EQ 0.075MG BASE | N207932 | 001 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | | EQ 0.075MG BASE | N207932 | 001 | Oct 23, 2015 | Jan | CTEC |
| >D> | AB | + | | EQ 0.15MG BASE | N207932 | 002 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | | EQ 0.15MG BASE | N207932 | 002 | Oct 23, 2015 | Jan | CTEC |
| >D> | AB | + | | EQ 0.3MG BASE | N207932 | 003 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | | EQ 0.3MG BASE | N207932 | 003 | Oct 23, 2015 | Jan | CTEC |
| >D> | AB | + | | EQ 0.45MG BASE | N207932 | 004 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | | EQ 0.45MG BASE | N207932 | 004 | Oct 23, 2015 | Jan | CTEC |
| >D> | AB | + | | EQ 0.6MG BASE | N207932 | 005 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | | EQ 0.6MG BASE | N207932 | 005 | Oct 23, 2015 | Jan | CTEC |
| >D> | AB | + | | EQ 0.75MG BASE | N207932 | 006 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | | EQ 0.75MG BASE | N207932 | 006 | Oct 23, 2015 | Jan | CTEC |
| >D> | AB | + | ! | EQ 0.9MG BASE | N207932 | 007 | Oct 23, 2015 | Jan | CTEC |
| >A> | | + | ! | EQ 0.9MG BASE | N207932 | 007 | Oct 23, 2015 | Jan | CTEC |

BUPRENORPHINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|--|---------|-----------------|---------|-----|--------------|-----|------|
| >D> | AB | | ALVOGEN | EQ 0.075MG BASE | A211594 | 001 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.075MG BASE | A211594 | 001 | Aug 03, 2021 | Jan | DISC |
| >D> | AB | | | EQ 0.15MG BASE | A211594 | 002 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.15MG BASE | A211594 | 002 | Aug 03, 2021 | Jan | DISC |
| >D> | AB | | | EQ 0.3MG BASE | A211594 | 003 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.3MG BASE | A211594 | 003 | Aug 03, 2021 | Jan | DISC |
| >D> | AB | | | EQ 0.45MG BASE | A211594 | 004 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.45MG BASE | A211594 | 004 | Aug 03, 2021 | Jan | DISC |
| >D> | AB | | | EQ 0.6MG BASE | A211594 | 005 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.6MG BASE | A211594 | 005 | Aug 03, 2021 | Jan | DISC |
| >D> | AB | | | EQ 0.75MG BASE | A211594 | 006 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.75MG BASE | A211594 | 006 | Aug 03, 2021 | Jan | DISC |
| >D> | AB | | | EQ 0.9MG BASE | A211594 | 007 | Aug 03, 2021 | Jan | DISC |
| >A> | | | @ | EQ 0.9MG BASE | A211594 | 007 | Aug 03, 2021 | Jan | DISC |

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

| | | | | | | | | | |
|-----|-----|--|----------|-------|---------|-----|--------------|-----|------|
| >A> | AB3 | | GRANULES | 150MG | A215568 | 001 | Feb 02, 2022 | Jan | NEWA |
| >A> | AB3 | | | 300MG | A215568 | 002 | Feb 02, 2022 | Jan | NEWA |

CAFFEINE CITRATE

SOLUTION; ORAL

CAFCIT

| | | | | | | | | | | |
|-----|----|---|---|------------------|------------------------------------|---------|-----|--------------|-----|------|
| >D> | AA | + | ! | HIKMA | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | N020793 | 002 | Apr 12, 2000 | Jan | DISC |
| >A> | | + | | @ | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | N020793 | 002 | Apr 12, 2000 | Jan | DISC |
| >D> | AA | | | CAFFEINE CITRATE | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | A077304 | 001 | Sep 21, 2006 | Jan | CHRS |
| >A> | AA | | ! | EXELA PHARMA | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | A077304 | 001 | Sep 21, 2006 | Jan | CHRS |

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

| | | | | | | | | | | |
|-----|----|---|---|--------------|-----------------------|---------|-----|--------------|-----|------|
| >A> | AB | | | RISING | 12.5MG; 200MG; 50MG | A213212 | 001 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | | | 18.75MG; 200MG; 75MG | A213212 | 002 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | | | 25MG; 200MG; 100MG | A213212 | 003 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | | | 31.25MG; 200MG; 125MG | A213212 | 004 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | | | 37.5MG; 200MG; 150MG | A213212 | 005 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | | | 50MG; 200MG; 200MG | A213212 | 006 | Jan 25, 2022 | Jan | NEWA |
| >D> | | + | | STALEVO 125 | 31.25MG; 200MG; 125MG | N021485 | 006 | Aug 29, 2008 | Jan | CTEC |
| >A> | AB | | + | ORION PHARMA | 31.25MG; 200MG; 125MG | N021485 | 006 | Aug 29, 2008 | Jan | CTEC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 200

| | | | | | | | | |
|-----|----|--------------|--------------------|---------|-----|--------------|-----|------|
| >D> | + | ORION PHARMA | 50MG;200MG;200MG | N021485 | 004 | Aug 02, 2007 | Jan | CTEC |
| >A> | AB | + | 50MG;200MG;200MG | N021485 | 004 | Aug 02, 2007 | Jan | CTEC |
| | | STALEVO 50 | | | | | | |
| >D> | + | ORION PHARMA | 12.5MG;200MG;50MG | N021485 | 001 | Jun 11, 2003 | Jan | CTEC |
| >A> | AB | + | 12.5MG;200MG;50MG | N021485 | 001 | Jun 11, 2003 | Jan | CTEC |
| | | STALEVO 75 | | | | | | |
| >D> | + | ORION PHARMA | 18.75MG;200MG;75MG | N021485 | 005 | Aug 29, 2008 | Jan | CTEC |
| >A> | AB | + | 18.75MG;200MG;75MG | N021485 | 005 | Aug 29, 2008 | Jan | CTEC |

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

| | | | | | | | | |
|-----|----|--------|-------------------|---------|-----|--------------|-----|------|
| >A> | AP | AMNEAL | EQ 0.25MG BASE/ML | A215337 | 001 | Jan 27, 2022 | Jan | NEWA |
|-----|----|--------|-------------------|---------|-----|--------------|-----|------|

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

| | | | | | | | | |
|-----|----|----------|------------------|---------|-----|--------------|-----|------|
| >D> | | @ ASTRAL | EQ 1GM BASE/VIAL | A212721 | 001 | Jul 21, 2020 | Jan | CMFD |
| >A> | AP | | EQ 1GM BASE/VIAL | A212721 | 001 | Jul 21, 2020 | Jan | CMFD |
| >D> | | @ | EQ 2GM BASE/VIAL | A212721 | 002 | Jul 21, 2020 | Jan | CMFD |
| >A> | AP | | EQ 2GM BASE/VIAL | A212721 | 002 | Jul 21, 2020 | Jan | CMFD |

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

| | | | | | | | | |
|-----|----|--------------------|------|---------|-----|--------------|-----|------|
| >D> | AB | VALEANT PHARM INTL | 5MG | A085461 | 001 | Sep 21, 1977 | Jan | CRLD |
| >A> | AB | + | 5MG | A085461 | 001 | Sep 21, 1977 | Jan | CRLD |
| >D> | AB | | 10MG | A085472 | 001 | Sep 21, 1977 | Jan | CRLD |
| >A> | AB | + | 10MG | A085472 | 001 | Sep 21, 1977 | Jan | CRLD |

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-----|-------|---------|-----|--------------|-----|------|
| >A> | AB | MSN | 25MG | A214827 | 001 | Jan 27, 2022 | Jan | NEWA |
| >A> | AB | | 50MG | A214827 | 002 | Jan 27, 2022 | Jan | NEWA |
| >A> | AB | | 100MG | A214827 | 003 | Jan 27, 2022 | Jan | NEWA |
| >A> | AB | | 200MG | A214827 | 004 | Jan 27, 2022 | Jan | NEWA |

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

| | | | | | | | | |
|-----|----|--------------|------|---------|-----|--------------|-----|------|
| >A> | AB | CHARTWELL RX | 25MG | A211063 | 001 | Feb 26, 2019 | Jan | CAHN |
| >A> | AB | | 50MG | A211063 | 002 | Feb 26, 2019 | Jan | CAHN |
| >A> | AB | INVENTIA | 25MG | A211320 | 001 | Feb 09, 2022 | Jan | NEWA |
| >A> | AB | | 50MG | A211320 | 002 | Feb 09, 2022 | Jan | NEWA |
| >A> | AB | SUNNY | 25MG | A209068 | 001 | Jan 25, 2022 | Jan | NEWA |
| >A> | AB | | 50MG | A209068 | 002 | Jan 25, 2022 | Jan | NEWA |
| >D> | AB | VISTAPHARM | 25MG | A211063 | 001 | Feb 26, 2019 | Jan | CAHN |
| >D> | AB | | 50MG | A211063 | 002 | Feb 26, 2019 | Jan | CAHN |

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

| | | | | | | | | |
|-----|----|-------------------|-----------------------|---------|-----|--------------|-----|------|
| >A> | AB | UPSHER SMITH LABS | EQ 4GM RESIN/PACKET | A214877 | 001 | Jan 21, 2022 | Jan | NEWA |
| >A> | AB | | EQ 4GM RESIN/SCOOPFUL | A214877 | 002 | Jan 21, 2022 | Jan | NEWA |

CIMETIDINE

TABLET; ORAL

CIMETIDINE

| | | | | | | | | |
|-----|--|--------------------|-------|---------|-----|--------------|-----|------|
| >A> | | @ CHARTWELL RX | 200MG | A074100 | 001 | Jan 31, 1995 | Jan | CAHN |
| >A> | | @ | 300MG | A074100 | 002 | Jan 31, 1995 | Jan | CAHN |
| >A> | | @ | 400MG | A074100 | 003 | Jan 31, 1995 | Jan | CAHN |
| >A> | | @ | 800MG | A074100 | 004 | Jan 31, 1995 | Jan | CAHN |
| >D> | | @ YAOPHARMA CO LTD | 200MG | A074100 | 001 | Jan 31, 1995 | Jan | CAHN |
| >D> | | @ | 300MG | A074100 | 002 | Jan 31, 1995 | Jan | CAHN |
| >D> | | @ | 400MG | A074100 | 003 | Jan 31, 1995 | Jan | CAHN |
| >D> | | @ | 800MG | A074100 | 004 | Jan 31, 1995 | Jan | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

| | | | | | | |
|-----|--------------------|---------------|--------------|--------------|-----|------|
| >A> | @ AIPING PHARM INC | EQ 250MG BASE | A 076593 002 | Jun 09, 2004 | Jan | CAHN |
| >A> | @ | EQ 500MG BASE | A 076593 003 | Jun 09, 2004 | Jan | CAHN |
| >A> | @ | EQ 750MG BASE | A 076593 004 | Jun 09, 2004 | Jan | CAHN |
| >D> | @ FOSUN PHARMA | EQ 250MG BASE | A 076593 002 | Jun 09, 2004 | Jan | CAHN |
| >D> | @ | EQ 500MG BASE | A 076593 003 | Jun 09, 2004 | Jan | CAHN |
| >D> | @ | EQ 750MG BASE | A 076593 004 | Jun 09, 2004 | Jan | CAHN |

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

| | | | | | | |
|-----|-------------|--------------|-------------|--------------|-----|------|
| >A> | +! ALMATICA | EQ 30MG BASE | N215428 001 | Jan 31, 2022 | Jan | NEWA |
|-----|-------------|--------------|-------------|--------------|-----|------|

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

| | | | | | | |
|-----|-----------------------|-------|--------------|--------------|-----|------|
| >A> | AB ALEMBIC PHARMS LTD | 250MG | A 210459 001 | Jan 31, 2022 | Jan | NEWA |
| >A> | AB | 500MG | A 210459 002 | Jan 31, 2022 | Jan | NEWA |

CLINDAMYCIN PHOSPHATE

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

| | | | | | | |
|-----|-----------|------------|--------------|--------------|-----|------|
| >A> | AB ENCUBE | EQ 1% BASE | A 215607 001 | Jan 18, 2022 | Jan | NEWA |
|-----|-----------|------------|--------------|--------------|-----|------|

CLONIDINE

TABLET, EXTENDED RELEASE; ORAL

NEXICLON XR

| | | | | | | |
|-----|-------------------|----------------|--------------|--------------|-----|------|
| >A> | @ ATHENA | EQ 0.17MG BASE | N 022500 001 | Dec 03, 2009 | Jan | CAHN |
| >A> | @ | EQ 0.26MG BASE | N 022500 002 | Dec 03, 2009 | Jan | CAHN |
| >D> | @ TRIS PHARMA INC | EQ 0.17MG BASE | N 022500 001 | Dec 03, 2009 | Jan | CAHN |
| >D> | @ | EQ 0.26MG BASE | N 022500 002 | Dec 03, 2009 | Jan | CAHN |

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

| | | | | | | |
|-----|--------|-------|--------------|--------------|-----|------|
| >A> | AB SPH | 625MG | A 213456 001 | Jan 21, 2022 | Jan | NEWA |
|-----|--------|-------|--------------|--------------|-----|------|

CYCLOSPORINE

EMULSION; OPHTHALMIC

CYCLOSPORINE

| | | | | | | |
|-----|-------------|-------|--------------|--------------|-----|------|
| >A> | AB MYLAN | 0.05% | A 205894 001 | Feb 02, 2022 | Jan | NFTG |
| >A> | AB RESTASIS | | | | | |
| >D> | +! ALLERGAN | 0.05% | N 050790 001 | Dec 23, 2002 | Jan | CFTG |
| >A> | AB +! | 0.05% | N 050790 001 | Dec 23, 2002 | Jan | CFTG |

DAPSONE

GEL; TOPICAL

DAPSONE

| | | | | | | |
|-----|----------|------|--------------|--------------|-----|------|
| >A> | AB MYLAN | 7.5% | A 213847 001 | Feb 04, 2022 | Jan | NEWA |
|-----|----------|------|--------------|--------------|-----|------|

TABLET; ORAL

DAPSONE

| | | | | | | |
|-----|------------------|-------|--------------|--------------|-----|------|
| >D> | AB VIRTUS PHARMS | 25MG | A 204074 001 | May 10, 2016 | Jan | DISC |
| >A> | @ | 25MG | A 204074 001 | May 10, 2016 | Jan | DISC |
| >D> | AB | 100MG | A 204074 002 | May 10, 2016 | Jan | DISC |
| >A> | @ | 100MG | A 204074 002 | May 10, 2016 | Jan | DISC |

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPZURA RT

| | | | | | | |
|-----|-------------------------|------------|--------------|--------------|-----|------|
| >A> | +! BAXTER HLTHCARE CORP | 500MG/VIAL | N 213645 001 | Jan 25, 2022 | Jan | NEWA |
|-----|-------------------------|------------|--------------|--------------|-----|------|

DEFERIPRONE

TABLET; ORAL

DEFERIPRONE

| | | | | | | |
|-----|----------|-----|--------------|--------------|-----|------|
| >A> | AB HIKMA | 1GM | A 213239 002 | Feb 08, 2022 | Jan | NFTG |
| >D> | + CHIESI | 1GM | N 021825 002 | Jul 25, 2019 | Jan | CFTG |
| >A> | AB + | 1GM | N 021825 002 | Jul 25, 2019 | Jan | CFTG |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

| | | | | | | | | |
|-----|----|--------------|---|----------|-----|--------------|-----|------|
| >D> | AB | MAYNE PHARMA | 0.15MG, N/A; 0.02MG, 0.01MG | A 076916 | 001 | Dec 29, 2008 | Jan | DISC |
| >A> | | @ | 0.15MG, N/A; 0.02MG, 0.01MG | A 076916 | 001 | Dec 29, 2008 | Jan | DISC |
| >D> | AB | | 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG | A 077182 | 001 | Jan 24, 2006 | Jan | DISC |
| >A> | | @ | 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG | A 077182 | 001 | Jan 24, 2006 | Jan | DISC |

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

| | | | | | | | | |
|-----|----|-------|-------|----------|-----|--------------|-----|------|
| >D> | BP | HIKMA | 0.5MG | A 084611 | 001 | Jul 25, 1975 | Jan | CRLD |
| >A> | BP | + | 0.5MG | A 084611 | 001 | Jul 25, 1975 | Jan | CRLD |

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

| | | | | | | | | |
|-----|----|------------------|-------|----------|-----|--------------|-----|------|
| >D> | AA | ARBOR PHARMS LLC | 2.5MG | A 090533 | 001 | Oct 25, 2011 | Jan | CTEC |
| >A> | | | 2.5MG | A 090533 | 001 | Oct 25, 2011 | Jan | CTEC |
| >D> | AA | | 7.5MG | A 090533 | 003 | Oct 25, 2011 | Jan | CTEC |
| >A> | | | 7.5MG | A 090533 | 003 | Oct 25, 2011 | Jan | CTEC |
| >D> | AA | | 15MG | A 090533 | 005 | Oct 25, 2011 | Jan | CTEC |
| >A> | | | 15MG | A 090533 | 005 | Oct 25, 2011 | Jan | CTEC |
| >D> | AA | | 20MG | A 090533 | 006 | Oct 25, 2011 | Jan | CTEC |
| >A> | | | 20MG | A 090533 | 006 | Oct 25, 2011 | Jan | CTEC |
| >D> | AA | | 30MG | A 090533 | 007 | Oct 25, 2011 | Jan | CTEC |
| >A> | | | 30MG | A 090533 | 007 | Oct 25, 2011 | Jan | CTEC |
| >D> | AA | WINDER LABS LLC | 2.5MG | A 212160 | 001 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 2.5MG | A 212160 | 001 | Jun 07, 2021 | Jan | DISC |
| >D> | AA | | 5MG | A 212160 | 002 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 5MG | A 212160 | 002 | Jun 07, 2021 | Jan | DISC |
| >D> | AA | | 7.5MG | A 212160 | 003 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 7.5MG | A 212160 | 003 | Jun 07, 2021 | Jan | DISC |
| >D> | AA | | 10MG | A 212160 | 004 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 10MG | A 212160 | 004 | Jun 07, 2021 | Jan | DISC |
| >D> | AA | | 15MG | A 212160 | 005 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 15MG | A 212160 | 005 | Jun 07, 2021 | Jan | DISC |
| >D> | AA | | 20MG | A 212160 | 006 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 20MG | A 212160 | 006 | Jun 07, 2021 | Jan | DISC |
| >D> | AA | | 30MG | A 212160 | 007 | Jun 07, 2021 | Jan | DISC |
| >A> | | @ | 30MG | A 212160 | 007 | Jun 07, 2021 | Jan | DISC |

DIGOXIN

TABLET; ORAL

DIGOXIN

| | | | | | | | | |
|-----|----|----------------------|----------|----------|-----|--------------|-----|------|
| >A> | AB | AUROBINDO PHARMA LTD | 0.0625MG | A 214982 | 001 | Feb 08, 2022 | Jan | NFTG |
| >A> | AB | | 0.125MG | A 214982 | 002 | Feb 08, 2022 | Jan | NEWA |
| >A> | AB | | 0.25MG | A 214982 | 003 | Feb 08, 2022 | Jan | NEWA |
| >D> | | LANOXIN | | | | | | |
| >D> | + | CONCORDIA | 0.0625MG | N 020405 | 001 | Sep 30, 1997 | Jan | CFTG |
| >A> | AB | + | 0.0625MG | N 020405 | 001 | Sep 30, 1997 | Jan | CFTG |

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------------------|------------|----------|-----|--------------|-----|------|
| >A> | AT | GLAND PHARMA LTD | EQ 2% BASE | A 215660 | 001 | Jan 27, 2022 | Jan | NEWA |
|-----|----|------------------|------------|----------|-----|--------------|-----|------|

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

| | | | | | | | | |
|-----|----|------------|--------------------------|----------|-----|--------------|-----|------|
| >A> | AT | MICRO LABS | EQ 2% BASE; EQ 0.5% BASE | A 215936 | 001 | Jan 25, 2022 | Jan | NEWA |
|-----|----|------------|--------------------------|----------|-----|--------------|-----|------|

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

| | | | | | | | | |
|-----|---|---------|-------------|----------|-----|--------------|-----|------|
| >D> | + | UPJOHN | EQ 4MG BASE | N 021269 | 001 | Feb 22, 2005 | Jan | CAHN |
| >D> | + | ! | EQ 8MG BASE | N 021269 | 002 | Feb 22, 2005 | Jan | CAHN |
| >A> | + | VIATRIS | EQ 4MG BASE | N 021269 | 001 | Feb 22, 2005 | Jan | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL
CARDURA XL

| | | | | | | | |
|-------------------------|----|-------------|---------|-----|--------------|-----|------|
| >A> | + | EQ 8MG BASE | N021269 | 002 | Feb 22, 2005 | Jan | CAHN |
| TABLET; ORAL CARDURA | | | | | | | |
| >D> | AB | EQ 1MG BASE | N019668 | 001 | Nov 02, 1990 | Jan | CAHN |
| >D> | AB | EQ 2MG BASE | N019668 | 002 | Nov 02, 1990 | Jan | CAHN |
| >D> | AB | EQ 4MG BASE | N019668 | 003 | Nov 02, 1990 | Jan | CAHN |
| >D> | AB | EQ 8MG BASE | N019668 | 004 | Nov 02, 1990 | Jan | CAHN |
| >A> | AB | EQ 1MG BASE | N019668 | 001 | Nov 02, 1990 | Jan | CAHN |
| >A> | AB | EQ 2MG BASE | N019668 | 002 | Nov 02, 1990 | Jan | CAHN |
| >A> | AB | EQ 4MG BASE | N019668 | 003 | Nov 02, 1990 | Jan | CAHN |
| >A> | AB | EQ 8MG BASE | N019668 | 004 | Nov 02, 1990 | Jan | CAHN |

DOXAZOSIN MESYLATE

| | | | | | | | |
|-----|---|-------------|---------|-----|--------------|-----|------|
| >A> | @ | EQ 1MG BASE | A075646 | 001 | Oct 18, 2000 | Jan | CAHN |
| >A> | @ | EQ 2MG BASE | A075646 | 002 | Oct 18, 2000 | Jan | CAHN |
| >A> | @ | EQ 4MG BASE | A075646 | 003 | Oct 18, 2000 | Jan | CAHN |
| >A> | @ | EQ 8MG BASE | A075646 | 004 | Oct 18, 2000 | Jan | CAHN |
| >D> | @ | EQ 1MG BASE | A075646 | 001 | Oct 18, 2000 | Jan | CAHN |
| >D> | @ | EQ 2MG BASE | A075646 | 002 | Oct 18, 2000 | Jan | CAHN |
| >D> | @ | EQ 4MG BASE | A075646 | 003 | Oct 18, 2000 | Jan | CAHN |
| >D> | @ | EQ 8MG BASE | A075646 | 004 | Oct 18, 2000 | Jan | CAHN |

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HYDROCHLORIDE

| | | | | | | | |
|-----|----|---------------|---------|-----|--------------|-----|------|
| >A> | AB | EQ 10MG BASE | A215710 | 001 | Feb 09, 2022 | Jan | NEWA |
| >A> | AB | EQ 25MG BASE | A215710 | 002 | Feb 09, 2022 | Jan | NEWA |
| >A> | AB | EQ 50MG BASE | A215710 | 003 | Feb 09, 2022 | Jan | NEWA |
| >A> | AB | EQ 75MG BASE | A215710 | 004 | Feb 09, 2022 | Jan | NEWA |
| >A> | AB | EQ 100MG BASE | A215710 | 005 | Feb 09, 2022 | Jan | NEWA |

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

| | | | | | | | |
|-----|---|-------------|---------|-----|--------------|-----|------|
| >D> | @ | EQ 3MG BASE | A202510 | 001 | Jul 24, 2020 | Jan | CAHN |
| >D> | @ | EQ 6MG BASE | A202510 | 002 | Jul 24, 2020 | Jan | CAHN |
| >A> | @ | EQ 3MG BASE | A202510 | 001 | Jul 24, 2020 | Jan | CAHN |
| >A> | @ | EQ 6MG BASE | A202510 | 002 | Jul 24, 2020 | Jan | CAHN |

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

| | | | | | | | |
|-----|----|--------------------|---------|-----|--------------|-----|------|
| >A> | AP | 2MCG/ML (2MCG/ML) | A213717 | 001 | Jan 24, 2022 | Jan | NEWA |
| >A> | AP | 4MCG/2ML (2MCG/ML) | A213717 | 002 | Jan 24, 2022 | Jan | NEWA |

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

| | | | | | | | |
|-----|----|---------------|---------|-----|--------------|-----|------|
| >D> | AB | EQ 100MG BASE | A209969 | 001 | Nov 09, 2018 | Jan | DISC |
| >A> | @ | EQ 100MG BASE | A209969 | 001 | Nov 09, 2018 | Jan | DISC |

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

| | | | | | | | |
|-----|----|---------------------|---------|-----|--------------|-----|------|
| >A> | AB | 600MG; 200MG; 300MG | A203053 | 001 | Jan 24, 2022 | Jan | NEWA |
|-----|----|---------------------|---------|-----|--------------|-----|------|

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOBY

| | | | | | | | |
|-----|---|---------------------|---------|-----|--------------|-----|------|
| >A> | + | 120MG; EQ 15MG BASE | N208215 | 002 | Jan 07, 2022 | Jan | NEWA |
|-----|---|---------------------|---------|-----|--------------|-----|------|

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

| | | | | | | | |
|-----|----|-----------|---------|-----|--------------|-----|------|
| >D> | AP | 1.25MG/ML | A075634 | 001 | Aug 22, 2000 | Jan | CHRS |
| >A> | AP | 1.25MG/ML | A075634 | 001 | Aug 22, 2000 | Jan | CHRS |
| >D> | AP | 1.25MG/ML | A078687 | 001 | Dec 23, 2008 | Jan | CHRS |
| >A> | AP | 1.25MG/ML | A078687 | 001 | Dec 23, 2008 | Jan | CHRS |
| >D> | AP | 1.25MG/ML | A075458 | 001 | Aug 22, 2000 | Jan | CHRS |
| >A> | AP | 1.25MG/ML | A075458 | 001 | Aug 22, 2000 | Jan | CHRS |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIGNOSPAN STANDARD

| | | | | | | | | |
|-----|---|---------|----------------------|----------|-----|--------------|-----|------|
| >D> | ! | DEPROCO | EQ 0.01MG BASE/ML;2% | A 088390 | 001 | Jan 22, 1985 | Jan | CRLD |
| >A> | + | ! | EQ 0.01MG BASE/ML;2% | A 088390 | 001 | Jan 22, 1985 | Jan | CRLD |

ESZOPICLONE

TABLET; ORAL
ESZOPICLONE

| | | | | | | | | |
|-----|---|---------------|-----|----------|-----|--------------|-----|------|
| >A> | @ | CHARTWELL RX | 1MG | A 091165 | 001 | Jul 14, 2011 | Jan | CAHN |
| >A> | @ | | 2MG | A 091165 | 002 | Jul 14, 2011 | Jan | CAHN |
| >A> | @ | | 3MG | A 091165 | 003 | Jul 14, 2011 | Jan | CAHN |
| >D> | @ | WOCKHARDT LTD | 1MG | A 091165 | 001 | Jul 14, 2011 | Jan | CAHN |
| >D> | @ | | 2MG | A 091165 | 002 | Jul 14, 2011 | Jan | CAHN |
| >D> | @ | | 3MG | A 091165 | 003 | Jul 14, 2011 | Jan | CAHN |

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28
ZOVIA 1/35E-28

| | | | | | | | | |
|-----|----|--------------|-------------|----------|-----|--------------|-----|------|
| >D> | AB | MAYNE PHARMA | 0.035MG;1MG | A 072721 | 001 | Dec 30, 1991 | Jan | DISC |
| >A> | @ | | 0.035MG;1MG | A 072721 | 001 | Dec 30, 1991 | Jan | DISC |

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL

| | | | | | | | | |
|-----|----|--------------|---------------|----------|-----|--------------|-----|------|
| >D> | AB | MAYNE PHARMA | 0.035MG;0.5MG | A 070686 | 001 | Jan 29, 1987 | Jan | DISC |
| >A> | @ | | 0.035MG;0.5MG | A 070686 | 001 | Jan 29, 1987 | Jan | DISC |

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET, CHEWABLE; ORAL
FINZALA

| | | | | | | | | |
|-----|----|---|------------|----------|-----|--------------|-----|------|
| >D> | @ | TEVA PHARMS USA INC | 0.02MG;1MG | A 210087 | 001 | Apr 07, 2020 | Jan | CMFD |
| >A> | AB | | 0.02MG;1MG | A 210087 | 001 | Apr 07, 2020 | Jan | CMFD |
| >D> | AB | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AMNEAL PHARMS | 0.02MG;1MG | A 207514 | 001 | Sep 11, 2017 | Jan | DISC |
| >A> | @ | | 0.02MG;1MG | A 207514 | 001 | Sep 11, 2017 | Jan | DISC |

TABLET; ORAL-21

| | | | | | | | | |
|-----|----|------------------------------------|--------------|----------|-----|--------------|-----|------|
| >D> | AB | MICROGESTIN 1.5/30 MAYNE PHARMA | 0.03MG;1.5MG | A 075548 | 002 | Jul 30, 2003 | Jan | DISC |
| >A> | @ | | 0.03MG;1.5MG | A 075548 | 002 | Jul 30, 2003 | Jan | DISC |
| >D> | AB | MICROGESTIN 1/20 MAYNE PHARMA | 0.02MG;1MG | A 075647 | 002 | Jul 30, 2003 | Jan | DISC |
| >A> | @ | | 0.02MG;1MG | A 075647 | 002 | Jul 30, 2003 | Jan | DISC |

TABLET; ORAL-28

| | | | | | | | | |
|-----|----|---|---------------------------------|----------|-----|--------------|-----|------|
| >D> | AB | MICROGESTIN FE 1.5/30 MAYNE PHARMA | 0.03MG;1.5MG | A 075548 | 001 | Feb 05, 2001 | Jan | DISC |
| >A> | @ | | 0.03MG;1.5MG | A 075548 | 001 | Feb 05, 2001 | Jan | DISC |
| >D> | AB | MICROGESTIN FE 1/20 MAYNE PHARMA | 0.02MG;1MG | A 075647 | 001 | Feb 05, 2001 | Jan | DISC |
| >A> | @ | | 0.02MG;1MG | A 075647 | 001 | Feb 05, 2001 | Jan | DISC |
| >D> | AB | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL MAYNE PHARMA | 0.02MG,0.03MG,0.035MG;1MG,1MG,1 | A 076629 | 001 | Mar 18, 2010 | Jan | DISC |
| >A> | @ | | 0.02MG,0.03MG,0.035MG;1MG,1MG,1 | A 076629 | 001 | Mar 18, 2010 | Jan | DISC |

ETONOGESTREL

IMPLANT; IMPLANTATION
IMPLANON

| | | | | | | | | |
|-----|---|-----------------|-----------------|----------|-----|--------------|-----|------|
| >A> | @ | ORGANON | 68MG/IMPLANT | N 021529 | 001 | Jul 17, 2006 | Jan | CAHN |
| >D> | @ | ORGANON USA INC | 68MG/IMPLANT | N 021529 | 001 | Jul 17, 2006 | Jan | CAHN |
| >A> | + | ! | ORGANON | N 021529 | 002 | May 31, 2011 | Jan | CAHN |
| >D> | + | ! | ORGANON USA INC | N 021529 | 002 | May 31, 2011 | Jan | CAHN |

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL
ALLEGRA

| | | | | | | | | |
|-----|---|-------------------|------|----------|-----|--------------|-----|------|
| >A> | @ | CHATTEM SANOFI | 60MG | N 020625 | 001 | Jul 25, 1996 | Jan | CAHN |
| >A> | @ | | 60MG | N 020625 | 001 | Jul 25, 1996 | Jan | CAHN |
| >D> | @ | SANOFI AVENTIS US | 60MG | N 020625 | 001 | Jul 25, 1996 | Jan | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

| | | | | | | | |
|-----|--------------------|-------|----------|-----|--------------|-----|------|
| >A> | @ CHARTWELL RX | 125MG | A 075818 | 001 | Sep 18, 2001 | Jan | CAHN |
| >D> | @ YAOPHARMA CO LTD | 125MG | A 075818 | 001 | Sep 18, 2001 | Jan | CAHN |

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

| | | | | | | | |
|-----|----------|--------------------|----------|-----|--------------|-----|------|
| >A> | AA CIPLA | EQ 3GM BASE/PACKET | A 211881 | 001 | Jan 26, 2022 | Jan | NEWA |
|-----|----------|--------------------|----------|-----|--------------|-----|------|

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FULVESTRANT

| | | | | | | | |
|-----|-----------|---------|----------|-----|--------------|-----|------|
| >D> | AO APOTEX | 50MG/ML | A 211730 | 001 | Jun 11, 2021 | Jan | DISC |
| >A> | @ | 50MG/ML | A 211730 | 001 | Jun 11, 2021 | Jan | DISC |

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

| | | | | | | | |
|-----|--------------|---------|----------|-----|--------------|-----|------|
| >A> | AP HONG KONG | 10MG/ML | A 212803 | 001 | Jan 27, 2022 | Jan | NEWA |
|-----|--------------|---------|----------|-----|--------------|-----|------|

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

| | | | | | | | |
|-----|--------------------------|---------------|----------|-----|--------------|-----|------|
| >D> | AB +! LG CHEM LTD | EQ 320MG BASE | N 021158 | 001 | Apr 04, 2003 | Jan | DISC |
| >A> | + @ | EQ 320MG BASE | N 021158 | 001 | Apr 04, 2003 | Jan | DISC |
| >D> | AB GEMIFLOXACIN MESYLATE | EQ 320MG BASE | A 090466 | 001 | Jun 15, 2015 | Jan | DISC |
| >A> | @ | EQ 320MG BASE | A 090466 | 001 | Jun 15, 2015 | Jan | DISC |

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|-----|--------------------|------------|----------|-----|--------------|-----|------|
| >A> | @ CHARTWELL RX | 25MG; 80MG | A 071061 | 001 | Aug 26, 1987 | Jan | CAHN |
| >D> | @ YAOPHARMA CO LTD | 25MG; 80MG | A 071061 | 001 | Aug 26, 1987 | Jan | CAHN |

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

| | | | | | | | |
|-----|-------------------|-------|----------|-----|--------------|-----|------|
| >D> | ! ACCORD HLTHCARE | 400MG | A 213342 | 004 | Aug 18, 2021 | Jan | CHRS |
| >A> | ! | 400MG | A 213342 | 004 | Aug 18, 2021 | Jan | CHRS |
| >A> | + NOVITIUM PHARMA | 200MG | N 214581 | 001 | Jan 14, 2022 | Jan | NEWA |
| >A> | +! | 300MG | N 214581 | 002 | Jan 14, 2022 | Jan | NEWA |

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

| | | | | | | | |
|-----|----------------------|----------|----------|-----|--------------|-----|------|
| >A> | @ PAI HOLDINGS PHARM | 10MG/5ML | A 040391 | 001 | Apr 10, 2002 | Jan | CAHN |
| >D> | @ VINTAGE PHARMS | 10MG/5ML | A 040391 | 001 | Apr 10, 2002 | Jan | CAHN |

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

| | | | | | | | |
|-----|-----------------------------|---------------|----------|-----|--------------|-----|------|
| >D> | AB + AMGEN INC | EQ 5MG BASE | N 206143 | 001 | Apr 15, 2015 | Jan | CTEC |
| >A> | + | EQ 5MG BASE | N 206143 | 001 | Apr 15, 2015 | Jan | CTEC |
| >D> | AB +! | EQ 7.5MG BASE | N 206143 | 002 | Apr 15, 2015 | Jan | CTEC |
| >A> | +! | EQ 7.5MG BASE | N 206143 | 002 | Apr 15, 2015 | Jan | CTEC |
| >D> | AB IVABRADINE HYDROCHLORIDE | EQ 5MG BASE | A 214051 | 001 | Dec 30, 2021 | Jan | DISC |
| >A> | @ | EQ 5MG BASE | A 214051 | 001 | Dec 30, 2021 | Jan | DISC |
| >D> | AB CENTAUR PHARMS PVT | EQ 7.5MG BASE | A 214051 | 002 | Dec 30, 2021 | Jan | DISC |
| >A> | @ | EQ 7.5MG BASE | A 214051 | 002 | Dec 30, 2021 | Jan | DISC |

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

| | | | | | | | |
|-----|--------------------------|-------|----------|-----|--------------|-----|------|
| >D> | AB + GLAXOSMITHKLINE LLC | 2MG | N 020764 | 004 | Sep 08, 2000 | Jan | CDFR |
| >D> | AB + | 5MG | N 020764 | 001 | Aug 24, 1998 | Jan | CDFR |
| >D> | AB +! | 25MG | N 020764 | 002 | Aug 24, 1998 | Jan | CDFR |
| >D> | @ | 100MG | N 020764 | 003 | Aug 24, 1998 | Jan | CDFR |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

| | | | | | | | | | |
|-----|------------------------------------|-----------------------|-------|---------|-----|--------------|-----|------|--|
| >D> | TABLET, CHEWABLE;ORAL | | | | | | | | |
| >D> | LAMOTRIGINE | | | | | | | | |
| >D> | AB | ALEMBIC PHARMS LTD | 5MG | A201168 | 001 | Jun 12, 2014 | Jan | CDFR | |
| >D> | AB | | 25MG | A201168 | 002 | Jun 12, 2014 | Jan | CDFR | |
| >D> | AB | AUROBINDO PHARMA | 5MG | A090401 | 002 | Nov 04, 2009 | Jan | CDFR | |
| >D> | AB | | 25MG | A090401 | 003 | Nov 04, 2009 | Jan | CDFR | |
| >D> | AB | DR REDDYS LABS LTD | 5MG | A076701 | 001 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | | 25MG | A076701 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | GLENMARK PHARMS LTD | 5MG | A079099 | 001 | Feb 19, 2009 | Jan | CDFR | |
| >D> | AB | | 25MG | A079099 | 002 | Feb 19, 2009 | Jan | CDFR | |
| >D> | | @ JUBILANT GENERICS | 5MG | A200220 | 001 | Feb 28, 2011 | Jan | CDFR | |
| >D> | | @ | 25MG | A200220 | 002 | Feb 28, 2011 | Jan | CDFR | |
| >D> | | @ MYLAN | 5MG | A076630 | 001 | Jan 22, 2009 | Jan | CDFR | |
| >D> | | @ | 25MG | A076630 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >D> | | @ SANDOZ | 5MG | A078409 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >D> | | @ | 25MG | A078409 | 003 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | TARO | 5MG | A079204 | 001 | Feb 04, 2009 | Jan | CDFR | |
| >D> | AB | | 25MG | A079204 | 002 | Feb 04, 2009 | Jan | CDFR | |
| >D> | | @ TEVA | 5MG | A076420 | 001 | Jun 21, 2006 | Jan | CDFR | |
| >D> | | @ | 25MG | A076420 | 002 | Jun 21, 2006 | Jan | CDFR | |
| >D> | AB | WATSON LABS | 2MG | A076928 | 001 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | | 5MG | A076928 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | | 25MG | A076928 | 003 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | ZYDUS PHARMS USA INC | 5MG | A078009 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >D> | AB | | 25MG | A078009 | 003 | Jan 22, 2009 | Jan | CDFR | |
| >A> | TABLET, FOR SUSPENSION;ORAL | | | | | | | | |
| >A> | LAMICTAL CD | | | | | | | | |
| >A> | AB | + GLAXOSMITHKLINE LLC | 2MG | N020764 | 004 | Sep 08, 2000 | Jan | CDFR | |
| >A> | AB | + | 5MG | N020764 | 001 | Aug 24, 1998 | Jan | CDFR | |
| >A> | AB | +! | 25MG | N020764 | 002 | Aug 24, 1998 | Jan | CDFR | |
| >A> | | @ | 100MG | N020764 | 003 | Aug 24, 1998 | Jan | CDFR | |
| >A> | LAMOTRIGINE | | | | | | | | |
| >A> | AB | ALEMBIC PHARMS LTD | 5MG | A201168 | 001 | Jun 12, 2014 | Jan | CDFR | |
| >A> | AB | | 25MG | A201168 | 002 | Jun 12, 2014 | Jan | CDFR | |
| >A> | AB | AUROBINDO PHARMA | 5MG | A090401 | 002 | Nov 04, 2009 | Jan | CDFR | |
| >A> | AB | | 25MG | A090401 | 003 | Nov 04, 2009 | Jan | CDFR | |
| >A> | AB | DR REDDYS LABS LTD | 5MG | A076701 | 001 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | | 25MG | A076701 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | GLENMARK PHARMS LTD | 5MG | A079099 | 001 | Feb 19, 2009 | Jan | CDFR | |
| >A> | AB | | 25MG | A079099 | 002 | Feb 19, 2009 | Jan | CDFR | |
| >A> | | @ JUBILANT GENERICS | 5MG | A200220 | 001 | Feb 28, 2011 | Jan | CDFR | |
| >A> | | @ | 25MG | A200220 | 002 | Feb 28, 2011 | Jan | CDFR | |
| >A> | | @ MYLAN | 5MG | A076630 | 001 | Jan 22, 2009 | Jan | CDFR | |
| >A> | | @ | 25MG | A076630 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >A> | | @ SANDOZ | 5MG | A078409 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >A> | | @ | 25MG | A078409 | 003 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | TARO | 5MG | A079204 | 001 | Feb 04, 2009 | Jan | CDFR | |
| >A> | AB | | 25MG | A079204 | 002 | Feb 04, 2009 | Jan | CDFR | |
| >A> | | @ TEVA | 5MG | A076420 | 001 | Jun 21, 2006 | Jan | CDFR | |
| >A> | | @ | 25MG | A076420 | 002 | Jun 21, 2006 | Jan | CDFR | |
| >A> | AB | WATSON LABS | 2MG | A076928 | 001 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | | 5MG | A076928 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | | 25MG | A076928 | 003 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | ZYDUS PHARMS USA INC | 5MG | A078009 | 002 | Jan 22, 2009 | Jan | CDFR | |
| >A> | AB | | 25MG | A078009 | 003 | Jan 22, 2009 | Jan | CDFR | |
| >A> | TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | | | |
| >A> | LAMOTRIGINE | | | | | | | | |
| >A> | AB | AMRING PHARMS | 25MG | A214124 | 001 | Feb 03, 2022 | Jan | NEWA | |
| >A> | AB | | 50MG | A214124 | 002 | Feb 03, 2022 | Jan | NEWA | |
| >A> | AB | | 100MG | A214124 | 003 | Feb 03, 2022 | Jan | NEWA | |
| >A> | AB | | 200MG | A214124 | 004 | Feb 03, 2022 | Jan | NEWA | |

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

| | | | | | | | | | |
|-----|----|------|---------------|---------|-----|--------------|-----|------|--|
| >A> | AB | BARR | EQ 500MG BASE | A090977 | 001 | Jan 27, 2022 | Jan | NEWA | |
| >A> | AB | | EQ 750MG BASE | A090977 | 002 | Jan 27, 2022 | Jan | NEWA | |
| >A> | AB | | EQ 1GM BASE | A090977 | 003 | Jan 27, 2022 | Jan | NEWA | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
LANTHANUM CARBONATE

| | | | | | | | | |
|-----|----|----------------|---------------|---------|-----|--------------|-----|------|
| >A> | AB | INVAGEN PHARMS | EQ 500MG BASE | A206868 | 001 | Jan 24, 2022 | Jan | NEWA |
| >A> | AB | | EQ 750MG BASE | A206868 | 002 | Jan 24, 2022 | Jan | NEWA |
| >A> | AB | | EQ 1GM BASE | A206868 | 003 | Jan 24, 2022 | Jan | NEWA |

LEFLUNOMIDE

TABLET; ORAL
LEFLUNOMIDE

| | | | | | | | | |
|-----|----|--------------|------|---------|-----|--------------|-----|------|
| >D> | | @ AET PHARMA | 10MG | A213497 | 001 | May 10, 2021 | Jan | CMFD |
| >A> | AB | | 10MG | A213497 | 001 | May 10, 2021 | Jan | CMFD |
| >D> | | @ | 20MG | A213497 | 002 | May 10, 2021 | Jan | CMFD |
| >A> | AB | | 20MG | A213497 | 002 | May 10, 2021 | Jan | CMFD |

LEUPROLIDE MESYLATE

EMULSION; SUBCUTANEOUS
CAMCEVI KIT

| | | | | | | | | |
|-----|--|-------------------|--------------|---------|-----|--------------|-----|------|
| >A> | | +! ACCORD | EQ 42MG BASE | N211488 | 001 | May 25, 2021 | Jan | CAHN |
| >D> | | +! FORESEE PHARMS | EQ 42MG BASE | N211488 | 001 | May 25, 2021 | Jan | CAHN |

LEVETIRACETAM

TABLET; ORAL
LEVETIRACETAM

| | | | | | | | | |
|-----|----|--------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | SECAN PHARMS | 500MG | A205102 | 004 | Dec 16, 2015 | Jan | DISC |
| >A> | | @ | 500MG | A205102 | 004 | Dec 16, 2015 | Jan | DISC |
| >D> | AB | | 1GM | A205102 | 003 | Dec 16, 2015 | Jan | DISC |
| >A> | | @ | 1GM | A205102 | 003 | Dec 16, 2015 | Jan | DISC |

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL
XYZAL

| | | | | | | | | |
|-----|--|--------------------|-----------|---------|-----|--------------|-----|------|
| >A> | | + @ CHATTEM SANOFI | 2.5MG/5ML | N022157 | 001 | Jan 28, 2008 | Jan | CAHN |
| >D> | | + @ SANOFI | 2.5MG/5ML | N022157 | 001 | Jan 28, 2008 | Jan | CAHN |

TABLET; ORAL
XYZAL

| | | | | | | | | |
|-----|--|--------------------|-----|---------|-----|--------------|-----|------|
| >A> | | + @ CHATTEM SANOFI | 5MG | N022064 | 001 | May 25, 2007 | Jan | CAHN |
| >D> | | + @ SANOFI | 5MG | N022064 | 001 | May 25, 2007 | Jan | CAHN |

LEVOTHYROXINE SODIUM

CAPSULE; ORAL
LEVOTHYROXINE SODIUM

| | | | | | | | | |
|-----|----|---------------------|---------|---------|-----|--------------|-----|------|
| >D> | AB | TEVA PHARMS USA INC | 0.112MG | A211369 | 003 | Apr 16, 2021 | Jan | DISC |
| >A> | | @ | 0.112MG | A211369 | 003 | Apr 16, 2021 | Jan | DISC |

TIROSINT
INSTITUT BIOCHIMIQUE

| | | | | | | | | |
|-----|----|------------------------|---------|---------|-----|--------------|-----|------|
| >D> | AB | + INSTITUT BIOCHIMIQUE | 0.112MG | N021924 | 008 | Oct 02, 2009 | Jan | CTEC |
| >A> | | + | 0.112MG | N021924 | 008 | Oct 02, 2009 | Jan | CTEC |

TABLET; ORAL
LEVOLET

| | | | | | | | | |
|-----|-----|----------------------|-------------------------|---------|-----|--------------|-----|------|
| >D> | | @ GENUS LIFESCIENCES | 0.025MG | N021137 | 001 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.025MG | N021137 | 001 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.05MG | N021137 | 002 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.05MG | N021137 | 002 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.075MG | N021137 | 003 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.075MG | N021137 | 003 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.088MG | N021137 | 004 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.088MG | N021137 | 004 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.1MG | N021137 | 005 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.1MG | N021137 | 005 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.112MG | N021137 | 006 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.112MG | N021137 | 006 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.125MG | N021137 | 007 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> 0.125MG | N021137 | 007 | Jun 06, 2003 | Jan | CMFD |
| >D> | | @ | AB1, AB3, AB 0.137MG | N021137 | 008 | Jun 06, 2003 | Jan | CMFD |
| >A> | --- | | --> AB1, 0.137MG | N021137 | 008 | Jun 06, 2003 | Jan | CMFD |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

| | | | | | | | | | |
|-----|-----|--------------|---------|---------|-----|--------------|-----|------|--|
| | | AB3, AB4 | | | | | | | |
| >D> | @ | 0.15MG | | N021137 | 009 | Jun 06, 2003 | Jan | CMFD | |
| >A> | --> | | 0.15MG | N021137 | 009 | Jun 06, 2003 | Jan | CMFD | |
| | | AB1, AB3, AB | | | | | | | |
| >D> | @ | 0.175MG | | N021137 | 010 | Jun 06, 2003 | Jan | CMFD | |
| >A> | --> | | 0.175MG | N021137 | 010 | Jun 06, 2003 | Jan | CMFD | |
| | | AB1, AB3, AB | | | | | | | |
| >D> | @ | 0.2MG | | N021137 | 011 | Jun 06, 2003 | Jan | CMFD | |
| >A> | --> | | 0.2MG | N021137 | 011 | Jun 06, 2003 | Jan | CMFD | |
| | | AB1, AB3, AB | | | | | | | |
| >D> | @ | 0.3MG | | N021137 | 012 | Jun 06, 2003 | Jan | CMFD | |
| >A> | --> | | 0.3MG | N021137 | 012 | Jun 06, 2003 | Jan | CMFD | |
| | | AB1, AB3, AB | | | | | | | |

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

| | | | | | | | | | |
|-----|----|---------------|------------|---------|-----|--------------|-----|------|--|
| >D> | AB | ACRUX DDS PTY | 2.5%; 2.5% | A212482 | 001 | Jul 27, 2021 | Jan | DISC | |
| >A> | @ | | 2.5%; 2.5% | A212482 | 001 | Jul 27, 2021 | Jan | DISC | |

LISINAPRIL

TABLET; ORAL

LISINAPRIL

| | | | | | | | | | |
|-----|---|----------------|-------|---------|-----|--------------|-----|------|--|
| >D> | @ | MYLAN | 2.5MG | A076071 | 001 | Jul 01, 2002 | Jan | CAHN | |
| >D> | @ | | 5MG | A076071 | 002 | Jul 01, 2002 | Jan | CAHN | |
| >D> | @ | | 10MG | A076071 | 003 | Jul 01, 2002 | Jan | CAHN | |
| >D> | @ | | 20MG | A076071 | 004 | Jul 01, 2002 | Jan | CAHN | |
| >D> | @ | | 30MG | A076071 | 005 | Jul 01, 2002 | Jan | CAHN | |
| >D> | @ | | 40MG | A076071 | 006 | Jul 01, 2002 | Jan | CAHN | |
| >A> | @ | STRIDES PHARMA | 2.5MG | A076071 | 001 | Jul 01, 2002 | Jan | CAHN | |
| >A> | @ | | 5MG | A076071 | 002 | Jul 01, 2002 | Jan | CAHN | |
| >A> | @ | | 10MG | A076071 | 003 | Jul 01, 2002 | Jan | CAHN | |
| >A> | @ | | 20MG | A076071 | 004 | Jul 01, 2002 | Jan | CAHN | |
| >A> | @ | | 30MG | A076071 | 005 | Jul 01, 2002 | Jan | CAHN | |
| >A> | @ | | 40MG | A076071 | 006 | Jul 01, 2002 | Jan | CAHN | |

LUBIPROSTONE

CAPSULE; ORAL

LUBIPROSTONE

| | | | | | | | | | |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|--|
| >A> | AB | DR REDDYS LABS LTD | 8MCG | A206994 | 001 | Feb 08, 2022 | Jan | NEWA | |
| >A> | AB | | 24MCG | A206994 | 002 | Feb 08, 2022 | Jan | NEWA | |
| >A> | AB | TEVA PHARMS USA INC | 8MCG | A209920 | 001 | Jan 18, 2022 | Jan | NEWA | |
| >A> | AB | | 24MCG | A209920 | 002 | Jan 18, 2022 | Jan | NEWA | |

MARAVIROC

TABLET; ORAL

MARAVIROC

| | | | | | | | | | |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|--|
| >A> | AB | HETERO LABS LTD III | 150MG | A203347 | 001 | Feb 07, 2022 | Jan | NFTG | |
| >A> | AB | | 300MG | A203347 | 002 | Feb 07, 2022 | Jan | NFTG | |
| | | SELZENTRY | | | | | | | |
| >D> | + | VIIV HLTHCARE | 150MG | N022128 | 001 | Aug 06, 2007 | Jan | CFTG | |
| >A> | AB | | 150MG | N022128 | 001 | Aug 06, 2007 | Jan | CFTG | |
| >D> | + | | 300MG | N022128 | 002 | Aug 06, 2007 | Jan | CFTG | |
| >A> | AB | | 300MG | N022128 | 002 | Aug 06, 2007 | Jan | CFTG | |

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|---|--------|------|---------|-----|--------------|-----|------|--|
| >D> | @ | MYLAN | 5MG | A079225 | 001 | Jan 30, 2015 | Jan | CAHN | |
| >D> | @ | | 10MG | A079225 | 002 | Jan 30, 2015 | Jan | CAHN | |
| >A> | @ | RISING | 5MG | A079225 | 001 | Jan 30, 2015 | Jan | CAHN | |
| >A> | @ | | 10MG | A079225 | 002 | Jan 30, 2015 | Jan | CAHN | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|-----|-----|------|-------|---------|-----|--------------|-----|------|
| >D> | AB2 | AMTA | 500MG | A213394 | 001 | Aug 03, 2021 | Jan | DISC |
| >A> | | @ | 500MG | A213394 | 001 | Aug 03, 2021 | Jan | DISC |
| >D> | AB2 | | 1GM | A213394 | 002 | Aug 03, 2021 | Jan | DISC |
| >A> | | @ | 1GM | A213394 | 002 | Aug 03, 2021 | Jan | DISC |

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

| | | | | | | | | |
|-----|--|--------------------------------|---------------------------------------|---------|-----|--------------|-----|------|
| >D> | | @ HOSPIRA | EQ 25MG BASE/ML | N011719 | 007 | Mar 31, 1982 | Jan | CRLD |
| >A> | | + @ | EQ 25MG BASE/ML | N011719 | 007 | Mar 31, 1982 | Jan | CRLD |
| | | METHOTREXATE PRESERVATIVE FREE | | | | | | |
| >D> | | @ HOSPIRA | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | N011719 | 014 | Apr 13, 2005 | Jan | CRLD |
| >A> | | + @ | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | N011719 | 014 | Apr 13, 2005 | Jan | CRLD |
| >D> | | @ | EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) | N011719 | 011 | Apr 13, 2005 | Jan | CRLD |
| >A> | | + @ | EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) | N011719 | 011 | Apr 13, 2005 | Jan | CRLD |

METHOTREXATE SODIUM

| | | | | | | | | |
|-----|--|-----------|--------------------|---------|-----|--------------|-----|------|
| >D> | | @ HOSPIRA | EQ 2.5MG BASE/ML | N011719 | 004 | Nov 01, 1971 | Jan | CRLD |
| >A> | | + @ | EQ 2.5MG BASE/ML | N011719 | 004 | Nov 01, 1971 | Jan | CRLD |
| >D> | | @ | EQ 20MG BASE/VIAL | N011719 | 001 | Aug 10, 1959 | Jan | CRLD |
| >A> | | + @ | EQ 20MG BASE/VIAL | N011719 | 001 | Aug 10, 1959 | Jan | CRLD |
| >D> | | @ | EQ 25MG BASE/ML | N011719 | 005 | Nov 01, 1971 | Jan | CRLD |
| >A> | | + @ | EQ 25MG BASE/ML | N011719 | 005 | Nov 01, 1971 | Jan | CRLD |
| >D> | | @ | EQ 50MG BASE/VIAL | N011719 | 003 | May 11, 1962 | Jan | CRLD |
| >A> | | + @ | EQ 50MG BASE/VIAL | N011719 | 003 | May 11, 1962 | Jan | CRLD |
| >D> | | @ | EQ 100MG BASE/VIAL | N011719 | 006 | Jan 09, 1962 | Jan | CRLD |
| >A> | | + @ | EQ 100MG BASE/VIAL | N011719 | 006 | Jan 09, 1962 | Jan | CRLD |

METHOTREXATE SODIUM PRESERVATIVE FREE

| | | | | | | | | |
|-----|----|-----------------|--------------------------------------|---------|-----|--------------|-----|------|
| >D> | AP | ! HIKMA | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A089343 | 001 | Sep 16, 1986 | Jan | CHRS |
| >A> | AP | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A089343 | 001 | Sep 16, 1986 | Jan | CHRS |
| >D> | | @ HOSPIRA | EQ 1GM BASE/VIAL | N011719 | 009 | Apr 07, 1988 | Jan | CRLD |
| >A> | | + @ | EQ 1GM BASE/VIAL | N011719 | 009 | Apr 07, 1988 | Jan | CRLD |
| | | MEXATE-AQ | | | | | | |
| >D> | | @ BRISTOL MYERS | EQ 25MG BASE/ML | A088760 | 001 | Feb 14, 1985 | Jan | CRLD |
| >A> | | + @ | EQ 25MG BASE/ML | A088760 | 001 | Feb 14, 1985 | Jan | CRLD |

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

| | | | | | | | | |
|-----|----|----------------------|---------|---------|-----|--------------|-----|------|
| >A> | AB | PAR STERILE PRODUCTS | 40MG/ML | A214297 | 001 | Jan 21, 2022 | Jan | NEWA |
| >A> | AB | | 80MG/ML | A214297 | 002 | Jan 21, 2022 | Jan | NEWA |

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

| | | | | | | | | |
|-----|----|--------------------|--------------------|---------|-----|--------------|-----|------|
| >D> | | @ TIANJIN KINGYORK | EQ 40MG BASE/VIAL | A212396 | 001 | Apr 20, 2021 | Jan | CMFD |
| >A> | AP | | EQ 40MG BASE/VIAL | A212396 | 001 | Apr 20, 2021 | Jan | CMFD |
| >D> | | @ | EQ 125MG BASE/VIAL | A212396 | 002 | Apr 20, 2021 | Jan | CMFD |
| >A> | AP | | EQ 125MG BASE/VIAL | A212396 | 002 | Apr 20, 2021 | Jan | CMFD |
| >D> | | @ | EQ 500MG BASE/VIAL | A212396 | 003 | Apr 20, 2021 | Jan | CMFD |
| >A> | AP | | EQ 500MG BASE/VIAL | A212396 | 003 | Apr 20, 2021 | Jan | CMFD |
| >D> | | @ | EQ 1GM BASE/VIAL | A212396 | 004 | Apr 20, 2021 | Jan | CMFD |
| >A> | AP | | EQ 1GM BASE/VIAL | A212396 | 004 | Apr 20, 2021 | Jan | CMFD |
| >D> | | @ | EQ 2GM BASE/VIAL | A212396 | 005 | Apr 20, 2021 | Jan | CMFD |
| >A> | AP | | EQ 2GM BASE/VIAL | A212396 | 005 | Apr 20, 2021 | Jan | CMFD |

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

REGLAN

| | | | | | | | | |
|-----|--|---------|----------------|---------|-----|--------------|-----|------|
| >D> | | @ HIKMA | EQ 5MG BASE/ML | N017862 | 001 | Feb 07, 1979 | Jan | CRLD |
| >A> | | + @ | EQ 5MG BASE/ML | N017862 | 001 | Feb 07, 1979 | Jan | CRLD |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

| | | | | | | | | |
|-----|----|------------------------------------|-------------|---------|-----|--------------|-----|------|
| >A> | AB | GLENMARK PHARMS LTD | 0.75% | A215794 | 001 | Jan 27, 2022 | Jan | NEWA |
| | | INJECTABLE; INJECTION | | | | | | |
| | | METRONIDAZOLE IN PLASTIC CONTAINER | | | | | | |
| >D> | | @ MYLAN LABS LTD | 500MG/100ML | A205531 | 001 | May 09, 2017 | Jan | CAHN |
| >A> | | @ RISING | 500MG/100ML | A205531 | 001 | May 09, 2017 | Jan | CAHN |

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

| | | | | | | | | |
|-----|--|----------------|----------------|---------|-----|--------------|-----|------|
| >D> | | @ MYLAN ASI | EQ 1MG BASE/ML | A090315 | 001 | Nov 29, 2010 | Jan | CAHN |
| >D> | | @ | EQ 5MG BASE/ML | A090315 | 002 | Nov 29, 2010 | Jan | CAHN |
| >A> | | @ STERISCIENCE | EQ 1MG BASE/ML | A090315 | 001 | Nov 29, 2010 | Jan | CAHN |
| >A> | | @ | EQ 5MG BASE/ML | A090315 | 002 | Nov 29, 2010 | Jan | CAHN |

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

| | | | | | | | | |
|-----|----|--------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | BRECKENRIDGE | 100MG | A209325 | 001 | Feb 03, 2022 | Jan | NEWA |
|-----|----|--------------|-------|---------|-----|--------------|-----|------|

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

| | | | | | | | | |
|-----|--|------------|--------------|---------|-----|--------------|-----|------|
| >A> | | +! JOURNEY | EQ 4% BASE | N212379 | 001 | Oct 18, 2019 | Jan | CAHN |
| >D> | | +! VYNE | EQ 4% BASE | N212379 | 001 | Oct 18, 2019 | Jan | CAHN |
| | | ZILXI | | | | | | |
| >A> | | +! JOURNEY | EQ 1.5% BASE | N213690 | 001 | May 28, 2020 | Jan | CAHN |
| >D> | | +! VYNE | EQ 1.5% BASE | N213690 | 001 | May 28, 2020 | Jan | CAHN |

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

| | | | | | | | | |
|-----|----|---------------|------|---------|-----|--------------|-----|------|
| >A> | AB | SQUARE PHARMS | 15MG | A205798 | 001 | Jun 01, 2017 | Jan | CAHN |
| >A> | AB | | 30MG | A205798 | 002 | Jun 01, 2017 | Jan | CAHN |
| >A> | AB | | 45MG | A205798 | 003 | Jun 01, 2017 | Jan | CAHN |
| >D> | AB | ZYDUS PHARMS | 15MG | A205798 | 001 | Jun 01, 2017 | Jan | CAHN |
| >D> | AB | | 30MG | A205798 | 002 | Jun 01, 2017 | Jan | CAHN |
| >D> | AB | | 45MG | A205798 | 003 | Jun 01, 2017 | Jan | CAHN |

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED; NASAL

RYALTRIS

| | | | | | | | | |
|-----|--|-----------------------|------------------------------|---------|-----|--------------|-----|------|
| >A> | | +! GLENMARK SPECIALTY | 0.025MG/SPRAY; 0.665MG/SPRAY | N211746 | 001 | Jan 13, 2022 | Jan | NEWA |
|-----|--|-----------------------|------------------------------|---------|-----|--------------|-----|------|

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

| | | | | | | | | |
|-----|----|-----------------------|---------|---------|-----|--------------|-----|------|
| >D> | AB | NORTEC DEV ASSOC | 20MG | A203158 | 001 | Aug 04, 2021 | Jan | DISC |
| >A> | | @ | 20MG | A203158 | 001 | Aug 04, 2021 | Jan | DISC |
| >D> | AB | | 30MG | A203158 | 002 | Aug 04, 2021 | Jan | DISC |
| >A> | | @ | 30MG | A203158 | 002 | Aug 04, 2021 | Jan | DISC |
| >D> | AB | | 50MG | A203158 | 003 | Aug 04, 2021 | Jan | DISC |
| >A> | | @ | 50MG | A203158 | 003 | Aug 04, 2021 | Jan | DISC |
| >D> | AB | | 60MG | A203158 | 004 | Aug 04, 2021 | Jan | DISC |
| >A> | | @ | 60MG | A203158 | 004 | Aug 04, 2021 | Jan | DISC |
| >D> | AB | | 80MG | A203158 | 005 | Aug 04, 2021 | Jan | DISC |
| >A> | | @ | 80MG | A203158 | 005 | Aug 04, 2021 | Jan | DISC |
| >D> | AB | | 100MG | A203158 | 006 | Aug 04, 2021 | Jan | DISC |
| >A> | | @ | 100MG | A203158 | 006 | Aug 04, 2021 | Jan | DISC |
| | | INJECTABLE; INJECTION | | | | | | |
| | | MORPHINE SULFATE | | | | | | |
| >D> | | +! HOSPIRA INC | 50MG/ML | N202515 | 006 | Apr 29, 2021 | Jan | DISC |
| >A> | | + @ | 50MG/ML | N202515 | 006 | Apr 29, 2021 | Jan | DISC |
| >D> | | @ INTL MEDICATION SYS | 1MG/ML | A202861 | 001 | Apr 29, 2021 | Jan | CMFD |
| >A> | | | 1MG/ML | A202861 | 001 | Apr 29, 2021 | Jan | CMFD |
| | | TABLET; ORAL | | | | | | |
| | | MORPHINE SULFATE | | | | | | |
| >A> | AB | RICONPHARMA LLC | 15MG | A215584 | 001 | Feb 07, 2022 | Jan | NEWA |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

TABLET; ORAL
MORPHINE SULFATE

>A> AB 30MG A215584 002 Feb 07, 2022 Jan NEWA

MYCOPHENOLATE MOFETIL

FOR SUSPENSION; ORAL
MYCOPHENOLATE MOFETIL

>A> AB 200MG/ML A211272 001 Jan 25, 2022 Jan NEWA

NALMEFENE HYDROCHLORIDE

>D> INJECTABLE; INJECTION
>D> REVEX
>D> + @ EUROHLTH INTL SARL EQ 0.1MG BASE/ML N020459 001 Apr 17, 1995 Jan CDFR
>D> + @ EQ 1MG BASE/ML N020459 002 Apr 17, 1995 Jan CDFR
SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
>A> NALMEFENE HYDROCHLORIDE
>A> ! PURDUE PHARMA LP EQ 2MG BASE/2ML (EQ 1MG BASE/ML) A212955 001 Feb 08, 2022 Jan NEWA

>A> REVEX
>A> + @ EUROHLTH INTL SARL EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) N020459 001 Apr 17, 1995 Jan CDFR
>A> + @ EQ 2MG BASE/2ML (EQ 1MG BASE/ML) N020459 002 Apr 17, 1995 Jan CDFR

NITROGLYCERIN

TABLET; SUBLINGUAL
NITROSTAT

>D> AB + UPJOHN 0.3MG N021134 001 May 01, 2000 Jan CAHN
>D> AB + 0.4MG N021134 002 May 01, 2000 Jan CAHN
>D> AB +! 0.6MG N021134 003 May 01, 2000 Jan CAHN
>A> AB + VIATRIS 0.3MG N021134 001 May 01, 2000 Jan CAHN
>A> AB + 0.4MG N021134 002 May 01, 2000 Jan CAHN
>A> AB +! 0.6MG N021134 003 May 01, 2000 Jan CAHN

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE; ORAL
MYCAPSSA

>A> +! AMRYT EQ 20MG BASE N208232 001 Jun 26, 2020 Jan CAHN
>D> +! CHIASMA EQ 20MG BASE N208232 001 Jun 26, 2020 Jan CAHN

OFLOXACIN

SOLUTION/DROPS; OTIC
OFLOXACIN

>A> AT FDC LTD 0.3% A215038 001 Jan 19, 2022 Jan NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

>D> @ MYLAN 10MG A075876 001 May 29, 2003 Jan CAHN
>D> @ 20MG A075876 002 May 29, 2003 Jan CAHN
>D> @ 40MG A075876 003 Jan 21, 2009 Jan CAHN
>A> @ STRIDES PHARMA 10MG A075876 001 May 29, 2003 Jan CAHN
>A> @ 20MG A075876 002 May 29, 2003 Jan CAHN
>A> @ 40MG A075876 003 Jan 21, 2009 Jan CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL
OSELTAMIVIR PHOSPHATE

>A> AB STRIDES PHARMA EQ 6MG BASE/ML A211894 001 Jan 13, 2022 Jan NEWA

OXAZEPAM

CAPSULE; ORAL
SERAX

>D> @ ALPHARMA US PHARMS 10MG N015539 002 Sep 29, 1966 Jan CRLD
>A> + @ 10MG N015539 002 Sep 29, 1966 Jan CRLD
>D> @ 15MG N015539 004 Sep 29, 1966 Jan CRLD
>A> + @ 15MG N015539 004 Sep 29, 1966 Jan CRLD
>D> @ 30MG N015539 006 Sep 29, 1966 Jan CRLD
>A> + @ 30MG N015539 006 Sep 29, 1966 Jan CRLD

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|---|---------|-----|--------------|-----|------|
| >D> | | EMCURE PHARMS LTD | EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | A202951 | 001 | Jun 29, 2021 | Jan | DISC |
| >A> | @ | | EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | A202951 | 001 | Jun 29, 2021 | Jan | DISC |
| >D> | AP | | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | A202951 | 002 | Jun 29, 2021 | Jan | DISC |
| >A> | @ | | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | A202951 | 002 | Jun 29, 2021 | Jan | DISC |

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|----------------------|----------------|---------|-----|--------------|-----|------|
| >D> | AB | SINOTHERAPEUTICS INC | EQ 12.5MG BASE | A213612 | 001 | Aug 11, 2021 | Jan | DISC |
| >A> | @ | | EQ 12.5MG BASE | A213612 | 001 | Aug 11, 2021 | Jan | DISC |
| >D> | AB | | EQ 25MG BASE | A213612 | 002 | Aug 11, 2021 | Jan | DISC |
| >A> | @ | | EQ 25MG BASE | A213612 | 002 | Aug 11, 2021 | Jan | DISC |

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

| | | | | | | | | |
|-----|-----|----------------------|-------------------|---------|-----|--------------|-----|------|
| >D> | AP1 | PAR STERILE PRODUCTS | 10MG/ML (10MG/ML) | A210025 | 001 | Dec 21, 2018 | Jan | DISC |
| >A> | @ | | 10MG/ML (10MG/ML) | A210025 | 001 | Dec 21, 2018 | Jan | DISC |

PIRFENIDONE

CAPSULE; ORAL

PIRFENIDONE

| | | | | | | | | |
|-----|----|-----------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | ACCORD HLTHCARE | 267MG | A212731 | 001 | Jan 20, 2022 | Jan | NEWA |
| >D> | AB | AMNEAL | 267MG | A212569 | 001 | Jan 03, 2022 | Jan | DISC |
| >A> | @ | | 267MG | A212569 | 001 | Jan 03, 2022 | Jan | DISC |

TABLET; ORAL

ESBRIET

| | | | | | | | | |
|-----|----|-----------------|-------|---------|-----|--------------|-----|------|
| >D> | + | GENENTECH INC | 267MG | N208780 | 001 | Jan 11, 2017 | Jan | CFTG |
| >A> | AB | + | 267MG | N208780 | 001 | Jan 11, 2017 | Jan | CFTG |
| >D> | + | ! | 801MG | N208780 | 003 | Jan 11, 2017 | Jan | CFTG |
| >A> | AB | + | 801MG | N208780 | 003 | Jan 11, 2017 | Jan | CFTG |
| >A> | AB | ACCORD HLTHCARE | 267MG | A212730 | 001 | Jan 25, 2022 | Jan | NFTG |
| >A> | AB | | 801MG | A212730 | 002 | Jan 25, 2022 | Jan | NFTG |
| >A> | AB | TEVA PHARMS USA | 267MG | A212759 | 001 | Jan 25, 2022 | Jan | NFTG |
| >A> | AB | | 801MG | A212759 | 002 | Jan 25, 2022 | Jan | NFTG |

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

| | | | | | | | | |
|-----|----|-------|-----|---------|-----|--------------|-----|------|
| >A> | AB | MYLAN | 1MG | A210275 | 001 | Jan 26, 2022 | Jan | NEWA |
| >A> | AB | | 2MG | A210275 | 002 | Jan 26, 2022 | Jan | NEWA |
| >A> | AB | | 3MG | A210275 | 003 | Jan 26, 2022 | Jan | NEWA |
| >A> | AB | | 4MG | A210275 | 004 | Jan 26, 2022 | Jan | NEWA |

POMALYST

| | | | | | | | | |
|-----|----|---------|-----|---------|-----|--------------|-----|------|
| >D> | + | CELGENE | 1MG | N204026 | 001 | Feb 08, 2013 | Jan | CTEC |
| >A> | AB | + | 1MG | N204026 | 001 | Feb 08, 2013 | Jan | CTEC |
| >D> | + | | 2MG | N204026 | 002 | Feb 08, 2013 | Jan | CTEC |
| >A> | AB | + | 2MG | N204026 | 002 | Feb 08, 2013 | Jan | CTEC |
| >D> | + | | 3MG | N204026 | 003 | Feb 08, 2013 | Jan | CTEC |
| >A> | AB | + | 3MG | N204026 | 003 | Feb 08, 2013 | Jan | CTEC |
| >D> | + | ! | 4MG | N204026 | 004 | Feb 08, 2013 | Jan | CTEC |
| >A> | AB | + | 4MG | N204026 | 004 | Feb 08, 2013 | Jan | CTEC |

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

NOXAFIL POWDERMIX KIT

| | | | | | | | | |
|-----|---|--------------|-------|---------|-----|--------------|-----|------|
| >D> | + | MSD MERCK CO | 300MG | N214770 | 001 | May 31, 2021 | Jan | DISC |
| >A> | + | @ | 300MG | N214770 | 001 | May 31, 2021 | Jan | DISC |

TABLET, DELAYED RELEASE; ORAL

POSACONAZOLE

| | | | | | | | | |
|-----|----|---------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | BIOCON PHARMA | 100MG | A214476 | 001 | Feb 04, 2022 | Jan | NEWA |
|-----|----|---------------|-------|---------|-----|--------------|-----|------|

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

| | | | | | | | | |
|-----|----|--------------------|------------|---------|-----|--------------|-----|------|
| >A> | AA | GRANULES | 20MEQ | A213467 | 001 | Jan 27, 2022 | Jan | NEWA |
| | | SOLUTION;ORAL | | | | | | |
| | | POTASSIUM CHLORIDE | | | | | | |
| >A> | AA | RUBICON | 20MEQ/15ML | A214656 | 001 | Jan 13, 2022 | Jan | NEWA |
| >A> | AA | | 40MEQ/15ML | A214656 | 002 | Jan 13, 2022 | Jan | NEWA |
| >A> | AA | TRIS PHARMA INC | 20MEQ/15ML | A214076 | 001 | Jan 26, 2022 | Jan | NEWA |
| >A> | AA | | 40MEQ/15ML | A214076 | 002 | Jan 26, 2022 | Jan | NEWA |

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------|---------|---------|-----|--------------|-----|------|
| >A> | AB | NOVAST LABS | 0.375MG | A213444 | 001 | Feb 03, 2022 | Jan | NEWA |
| >A> | AB | | 0.75MG | A213444 | 002 | Feb 03, 2022 | Jan | NEWA |
| >A> | AB | | 1.5MG | A213444 | 003 | Feb 03, 2022 | Jan | NEWA |
| >A> | AB | | 2.25MG | A213444 | 004 | Feb 03, 2022 | Jan | NEWA |
| >A> | AB | | 3MG | A213444 | 005 | Feb 03, 2022 | Jan | NEWA |
| >A> | AB | | 3.75MG | A213444 | 006 | Feb 03, 2022 | Jan | NEWA |
| >A> | AB | | 4.5MG | A213444 | 007 | Feb 03, 2022 | Jan | NEWA |

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

| | | | | | | | | |
|-----|----|------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | VKT PHARMA | 500MG | A214035 | 001 | Jan 19, 2022 | Jan | NEWA |
| >A> | AB | | 1GM | A214035 | 002 | Jan 19, 2022 | Jan | NEWA |

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

| | | | | | | | | |
|-----|----|-----------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | DR REDDYS | EQ 0.5MG BASE | A201942 | 001 | Nov 18, 2021 | Jan | DISC |
| >A> | | @ | EQ 0.5MG BASE | A201942 | 001 | Nov 18, 2021 | Jan | DISC |
| >D> | AB | | EQ 1MG BASE | A201942 | 002 | Nov 18, 2021 | Jan | DISC |
| >A> | | @ | EQ 1MG BASE | A201942 | 002 | Nov 18, 2021 | Jan | DISC |

RILUZOLE

SUSPENSION;ORAL

TIGLUTIK KIT

| | | | | | | | | |
|-----|---|-----------------|-----------|---------|-----|--------------|-----|------|
| >D> | + | ITALFARMACO SPA | 50MG/10ML | N209080 | 001 | Sep 05, 2018 | Jan | CAHN |
| >A> | + | | 50MG/10ML | N209080 | 001 | Sep 05, 2018 | Jan | CAHN |

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

| | | | | | | | | |
|-----|--|------------------|--------------|---------|-----|--------------|-----|------|
| >D> | | @ MYLAN | EQ 5MG BASE | A079161 | 001 | Jul 19, 2016 | Jan | CAHN |
| >D> | | @ | EQ 10MG BASE | A079161 | 002 | Jul 19, 2016 | Jan | CAHN |
| >D> | | @ | EQ 20MG BASE | A079161 | 003 | Jul 19, 2016 | Jan | CAHN |
| >D> | | @ | EQ 40MG BASE | A079161 | 004 | Jul 19, 2016 | Jan | CAHN |
| >A> | | @ STRIDES PHARMA | EQ 5MG BASE | A079161 | 001 | Jul 19, 2016 | Jan | CAHN |
| >A> | | @ | EQ 10MG BASE | A079161 | 002 | Jul 19, 2016 | Jan | CAHN |
| >A> | | @ | EQ 20MG BASE | A079161 | 003 | Jul 19, 2016 | Jan | CAHN |
| >A> | | @ | EQ 40MG BASE | A079161 | 004 | Jul 19, 2016 | Jan | CAHN |

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

| | | | | | | | | |
|-----|---|------------------|----------|---------|-----|--------------|-----|------|
| >D> | + | LANTHEUS MEDICAL | 50mCi/ML | N020570 | 001 | Mar 28, 1997 | Jan | DISC |
| >A> | + | @ | 50mCi/ML | N020570 | 001 | Mar 28, 1997 | Jan | DISC |

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

ZOLOFT

| | | | | | | | | | |
|-----|----|---|---------|-----------------|---------|-----|--------------|-----|------|
| >D> | AA | + | UPJOHN | EQ 20MG BASE/ML | N020990 | 001 | Dec 07, 1999 | Jan | CAHN |
| >A> | AA | + | VIATRIS | EQ 20MG BASE/ML | N020990 | 001 | Dec 07, 1999 | Jan | CAHN |

TABLET;ORAL

ZOLOFT

| | | | | | | | | | |
|-----|----|---|--------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | + | UPJOHN | EQ 25MG BASE | N019839 | 005 | Mar 06, 1996 | Jan | CAHN |
| >D> | AB | + | | EQ 50MG BASE | N019839 | 001 | Dec 30, 1991 | Jan | CAHN |
| >D> | AB | + | | EQ 100MG BASE | N019839 | 002 | Dec 30, 1991 | Jan | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

ZOLOFT

| | | | | | | | | | |
|-----|----|---|---------------|---------------|---------|--------------|--------------|------|------|
| >D> | + | @ | EQ 150MG BASE | N019839 | 003 | Dec 30, 1991 | Jan | CAHN | |
| >D> | + | @ | EQ 200MG BASE | N019839 | 004 | Dec 30, 1991 | Jan | CAHN | |
| >A> | AB | + | VIATRIS | EQ 25MG BASE | N019839 | 005 | Mar 06, 1996 | Jan | CAHN |
| >A> | AB | + | | EQ 50MG BASE | N019839 | 001 | Dec 30, 1991 | Jan | CAHN |
| >A> | AB | + | ! | EQ 100MG BASE | N019839 | 002 | Dec 30, 1991 | Jan | CAHN |
| >A> | | + | @ | EQ 150MG BASE | N019839 | 003 | Dec 30, 1991 | Jan | CAHN |
| >A> | | + | @ | EQ 200MG BASE | N019839 | 004 | Dec 30, 1991 | Jan | CAHN |

SEVELAMER CARBONATE

TABLET; ORAL

SEVELAMER CARBONATE

| | | | | | | | | | |
|-----|----|---|----------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | | MICRO LABS | 800MG | A215537 | 001 | Feb 07, 2022 | Jan | NEWA |
| >D> | | @ | MYLAN | 800MG | A201069 | 001 | Aug 05, 2020 | Jan | CAHN |
| >A> | | @ | STRIDES PHARMA | 800MG | A201069 | 001 | Aug 05, 2020 | Jan | CAHN |

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

SILDENAFIL CITRATE

| | | | | | | | | | |
|-----|----|--|-----|-----------------|---------|-----|--------------|-----|------|
| >A> | AB | | MSN | EQ 10MG BASE/ML | A214641 | 001 | Feb 08, 2022 | Jan | NEWA |
|-----|----|--|-----|-----------------|---------|-----|--------------|-----|------|

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

| | | | | | | | | | |
|-----|----|---|-----------|---------|---------|-----|--------------|-----|------|
| >D> | AP | | BE PHARMS | 25MG/ML | A214971 | 001 | Jul 12, 2021 | Jan | DISC |
| >A> | | @ | | 25MG/ML | A214971 | 001 | Jul 12, 2021 | Jan | DISC |

SOFOBUVIR

TABLET; ORAL

SOFOBUVIR

| | | | | | | | | | | |
|-----|----|---|---------------------|---------------------|---------|---------|--------------|--------------|------|------|
| >A> | AB | | TEVA PHARMS USA INC | 400MG | A211353 | 001 | Jan 27, 2022 | Jan | NFTG | |
| >D> | | + | ! | GILEAD SCIENCES INC | 400MG | N204671 | 001 | Dec 06, 2013 | Jan | CFTG |
| >A> | AB | + | ! | | 400MG | N204671 | 001 | Dec 06, 2013 | Jan | CFTG |

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

| | | | | | | | | | |
|-----|----|---|------------------|------|---------|-----|--------------|-----|------|
| >D> | AB | | AMNEAL PHARMS CO | 5MG | A209719 | 001 | May 20, 2019 | Jan | DISC |
| >A> | | @ | | 5MG | A209719 | 001 | May 20, 2019 | Jan | DISC |
| >D> | AB | | | 10MG | A209719 | 002 | May 20, 2019 | Jan | DISC |
| >A> | | @ | | 10MG | A209719 | 002 | May 20, 2019 | Jan | DISC |

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

| | | | | | | | | | |
|-----|----|--|-----------|---------|---------|-----|--------------|-----|------|
| >A> | AP | | BE PHARMS | 20MG/ML | A216003 | 001 | Feb 07, 2022 | Jan | NEWA |
|-----|----|--|-----------|---------|---------|-----|--------------|-----|------|

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

| | | | | | | | | | |
|-----|----|--|-----------------|---------------------|---------|-----|--------------|-----|------|
| >A> | AB | | NOVITIUM PHARMA | 200MG/5ML; 40MG/5ML | A214330 | 001 | Feb 08, 2022 | Jan | NEWA |
|-----|----|--|-----------------|---------------------|---------|-----|--------------|-----|------|

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

TAFLUPROST

| | | | | | | | | | |
|-----|----|--|------------|---------|---------|-----|--------------|-----|------|
| >A> | AT | | SANDOZ INC | 0.0015% | A209040 | 001 | Jan 28, 2022 | Jan | NEWA |
|-----|----|--|------------|---------|---------|-----|--------------|-----|------|

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

| | | | | | | | | | |
|-----|----|---|----------|-------|---------|-----|--------------|-----|------|
| >D> | | @ | HERITAGE | 5MG | A078879 | 001 | Mar 01, 2010 | Jan | CMFD |
| >A> | AB | | | 5MG | A078879 | 001 | Mar 01, 2010 | Jan | CMFD |
| >D> | | @ | | 20MG | A078879 | 002 | Mar 01, 2010 | Jan | CMFD |
| >A> | AB | | | 20MG | A078879 | 002 | Mar 01, 2010 | Jan | CMFD |
| >D> | | @ | | 100MG | A078879 | 003 | Mar 01, 2010 | Jan | CMFD |
| >A> | AB | | | 100MG | A078879 | 003 | Mar 01, 2010 | Jan | CMFD |
| >D> | | @ | | 140MG | A078879 | 005 | Mar 01, 2010 | Jan | CMFD |
| >A> | AB | | | 140MG | A078879 | 005 | Mar 01, 2010 | Jan | CMFD |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

| | | | | | | | |
|-----|----|-------|----------|-----|--------------|-----|------|
| >D> | @ | 180MG | A 078879 | 006 | Mar 01, 2010 | Jan | CMFD |
| >A> | AB | 180MG | A 078879 | 006 | Mar 01, 2010 | Jan | CMFD |
| >D> | @ | 250MG | A 078879 | 004 | Mar 01, 2010 | Jan | CMFD |
| >A> | AB | 250MG | A 078879 | 004 | Mar 01, 2010 | Jan | CMFD |

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

| | | | | | | | | | |
|-----|-----|---|--------|-------------------------------|----------|-----|--------------|-----|------|
| >D> | AB2 | + | ABBVIE | 1.62% (20.25MG/1.25GM PACKET) | N 022309 | 002 | Sep 07, 2012 | Jan | DISC |
| >A> | | + | @ | 1.62% (20.25MG/1.25GM PACKET) | N 022309 | 002 | Sep 07, 2012 | Jan | DISC |
| >D> | AB2 | + | ! | 1.62% (40.5MG/2.5GM PACKET) | N 022309 | 003 | Sep 07, 2012 | Jan | DISC |
| >A> | | + | @ | 1.62% (40.5MG/2.5GM PACKET) | N 022309 | 003 | Sep 07, 2012 | Jan | DISC |
| >D> | AB1 | + | | 25MG/2.5GM PACKET | N 021015 | 001 | Feb 28, 2000 | Jan | DISC |
| >A> | | + | @ | 25MG/2.5GM PACKET | N 021015 | 001 | Feb 28, 2000 | Jan | DISC |
| >D> | AB1 | + | ! | 50MG/5GM PACKET | N 021015 | 002 | Feb 28, 2000 | Jan | DISC |
| >A> | | + | @ | 50MG/5GM PACKET | N 021015 | 002 | Feb 28, 2000 | Jan | DISC |

TESTOSTERONE

| | | | | | | | | | |
|-----|-----|--|---------------------|-----------------------------|----------|-----|--------------|-----|------|
| >D> | AB1 | | ACTAVIS LABS UT INC | 50MG/5GM PACKET | A 076737 | 002 | Jan 27, 2006 | Jan | CHRS |
| >A> | AB1 | | ! | 50MG/5GM PACKET | A 076737 | 002 | Jan 27, 2006 | Jan | CHRS |
| >D> | AB2 | | PADAGIS ISRAEL | 1.62% (40.5MG/2.5GM PACKET) | A 205781 | 002 | Jul 12, 2017 | Jan | CHRS |
| >A> | AB2 | | ! | 1.62% (40.5MG/2.5GM PACKET) | A 205781 | 002 | Jul 12, 2017 | Jan | CHRS |

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL

TOFACITINIB

| | | | | | | | | | |
|-----|----|---|--------------|--------------|----------|-----|--------------|-----|------|
| >D> | AB | | ZYDUS PHARMS | EQ 11MG BASE | A 214264 | 001 | Aug 19, 2021 | Jan | DISC |
| >A> | | | @ | EQ 11MG BASE | A 214264 | 001 | Aug 19, 2021 | Jan | DISC |
| >D> | AB | | | EQ 22MG BASE | A 214264 | 002 | Aug 19, 2021 | Jan | DISC |
| >A> | | | @ | EQ 22MG BASE | A 214264 | 002 | Aug 19, 2021 | Jan | DISC |
| | | | XELJANZ XR | | | | | | |
| >D> | AB | + | PFIZER | EQ 11MG BASE | N 208246 | 001 | Feb 23, 2016 | Jan | CTEC |
| >A> | | + | | EQ 11MG BASE | N 208246 | 001 | Feb 23, 2016 | Jan | CTEC |
| >D> | AB | + | ! | EQ 22MG BASE | N 208246 | 002 | Dec 12, 2019 | Jan | CTEC |
| >A> | | + | ! | EQ 22MG BASE | N 208246 | 002 | Dec 12, 2019 | Jan | CTEC |

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

NASACORT

| | | | | | | | | | |
|-----|--|--|---------------------|-------------|----------|-----|--------------|-----|------|
| >A> | | | @ CHATTEM SANOFI | 0.055MG/INH | N 019798 | 001 | Jul 11, 1991 | Jan | CAHN |
| >A> | | | @ | 0.055MG/INH | N 019798 | 001 | Jul 11, 1991 | Jan | CAHN |
| >D> | | | @ SANOFI AVENTIS US | 0.055MG/INH | N 019798 | 001 | Jul 11, 1991 | Jan | CAHN |

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

| | | | | | | | | | |
|-----|----|--|-------------------------|---------------|----------|-----|--------------|-----|------|
| >A> | AB | | LONG GROVE PHARMS | 40MG/ML | A 213543 | 001 | Jan 19, 2022 | Jan | CAHN |
| | | | SPRAY, METERED; NASAL | | | | | | |
| | | | TRIAMCINOLONE ACETONIDE | | | | | | |
| >D> | | | @ PERRIGO | 0.055MG/SPRAY | A 078104 | 001 | Jul 30, 2009 | Jan | CAHN |
| >A> | | | @ PERRIGO PHARMA INTL | 0.055MG/SPRAY | A 078104 | 001 | Jul 30, 2009 | Jan | CAHN |

UPADACITINIB

TABLET, EXTENDED RELEASE; ORAL

RINVOQ

| | | | | | | | | | |
|-----|--|---|------------|------|----------|-----|--------------|-----|------|
| >D> | | + | ABBVIE INC | 15MG | N 211675 | 001 | Aug 16, 2019 | Jan | CHRS |
| >A> | | + | | 15MG | N 211675 | 001 | Aug 16, 2019 | Jan | CHRS |
| >A> | | + | ! | 30MG | N 211675 | 002 | Jan 14, 2022 | Jan | NEWA |

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

| | | | | | | | | | |
|-----|--|--|--------------|--------------------|----------|-----|--------------|-----|------|
| >D> | | | @ ANI PHARMS | EQ 500MG BASE/VIAL | A 060180 | 001 | Nov 06, 1964 | Jan | CAHN |
| >D> | | | @ | EQ 500MG BASE/VIAL | A 062476 | 001 | Mar 15, 1984 | Jan | CAHN |
| >D> | | | @ | EQ 500MG BASE/VIAL | A 062716 | 001 | Mar 13, 1987 | Jan | CAHN |
| >D> | | | @ | EQ 500MG BASE/VIAL | A 062812 | 001 | Nov 17, 1987 | Jan | CAHN |
| >D> | | | @ | EQ 1GM BASE/VIAL | A 060180 | 002 | Mar 21, 1986 | Jan | CAHN |
| >D> | | | @ | EQ 1GM BASE/VIAL | A 062476 | 002 | Mar 21, 1986 | Jan | CAHN |
| >D> | | | @ | EQ 1GM BASE/VIAL | A 062716 | 002 | Mar 13, 1987 | Jan | CAHN |
| >D> | | | @ | EQ 1GM BASE/VIAL | A 062812 | 002 | Nov 17, 1987 | Jan | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOGIN HYDROCHLORIDE

| | | | | | | | | |
|-----|---|--------------|--------------------|---------|-----|--------------|-----|------|
| >D> | @ | | EQ 10GM BASE/VIAL | A062812 | 003 | Nov 17, 1987 | Jan | CAHN |
| >A> | @ | STERISCIENCE | EQ 500MG BASE/VIAL | A060180 | 001 | Nov 06, 1964 | Jan | CAHN |
| >A> | @ | | EQ 500MG BASE/VIAL | A062476 | 001 | Mar 15, 1984 | Jan | CAHN |
| >A> | @ | | EQ 500MG BASE/VIAL | A062716 | 001 | Mar 13, 1987 | Jan | CAHN |
| >A> | @ | | EQ 500MG BASE/VIAL | A062812 | 001 | Nov 17, 1987 | Jan | CAHN |
| >A> | @ | | EQ 1GM BASE/VIAL | A060180 | 002 | Mar 21, 1986 | Jan | CAHN |
| >A> | @ | | EQ 1GM BASE/VIAL | A062476 | 002 | Mar 21, 1986 | Jan | CAHN |
| >A> | @ | | EQ 1GM BASE/VIAL | A062716 | 002 | Mar 13, 1987 | Jan | CAHN |
| >A> | @ | | EQ 1GM BASE/VIAL | A062812 | 002 | Nov 17, 1987 | Jan | CAHN |
| >A> | @ | | EQ 10GM BASE/VIAL | A062812 | 003 | Nov 17, 1987 | Jan | CAHN |

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|----------------|---------|-----|--------------|-----|------|
| >D> | AB | YICHANG HUMANWELL | EQ 37.5MG BASE | A214654 | 001 | Aug 06, 2021 | Jan | DISC |
| >A> | @ | | EQ 37.5MG BASE | A214654 | 001 | Aug 06, 2021 | Jan | DISC |
| >D> | AB | | EQ 75MG BASE | A214654 | 002 | Aug 06, 2021 | Jan | DISC |
| >A> | @ | | EQ 75MG BASE | A214654 | 002 | Aug 06, 2021 | Jan | DISC |
| >D> | AB | | EQ 150MG BASE | A214654 | 003 | Aug 06, 2021 | Jan | DISC |
| >A> | @ | | EQ 150MG BASE | A214654 | 003 | Aug 06, 2021 | Jan | DISC |

VIGABATRIN

TABLET; ORAL

VIGABATRIN

| | | | | | | | | |
|-----|----|-------|-------|---------|-----|--------------|-----|------|
| >A> | AB | ZYDUS | 500MG | A215707 | 001 | Jan 19, 2022 | Jan | NEWA |
|-----|----|-------|-------|---------|-----|--------------|-----|------|

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

| | | | | | | | | |
|-----|----|------------|--------------|---------|-----|--------------|-----|------|
| >D> | AB | +! UPJOHN | EQ 20MG BASE | N020825 | 001 | Feb 05, 2001 | Jan | CAHN |
| >D> | AB | + | EQ 40MG BASE | N020825 | 002 | Feb 05, 2001 | Jan | CAHN |
| >D> | AB | + | EQ 60MG BASE | N020825 | 003 | Feb 05, 2001 | Jan | CAHN |
| >D> | AB | + | EQ 80MG BASE | N020825 | 004 | Feb 05, 2001 | Jan | CAHN |
| >A> | AB | +! VIATRIS | EQ 20MG BASE | N020825 | 001 | Feb 05, 2001 | Jan | CAHN |
| >A> | AB | + | EQ 40MG BASE | N020825 | 002 | Feb 05, 2001 | Jan | CAHN |
| >A> | AB | + | EQ 60MG BASE | N020825 | 003 | Feb 05, 2001 | Jan | CAHN |
| >A> | AB | + | EQ 80MG BASE | N020825 | 004 | Feb 05, 2001 | Jan | CAHN |

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

| | | | | | | | | |
|-----|----|------------|-----------------|---------|-----|--------------|-----|------|
| >D> | AP | +! UPJOHN | EQ 20MG BASE/ML | N020919 | 001 | Jun 21, 2002 | Jan | CAHN |
| >A> | AP | +! VIATRIS | EQ 20MG BASE/ML | N020919 | 001 | Jun 21, 2002 | Jan | CAHN |

ADDITIONS/DELETIONS FOR OTC DRUG PRODUCT LIST

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

| | | | | | | | |
|-----|----------------------|------------------|---------|-----|--------------|-----|------|
| >A> | AUROBINDO PHARMA LTD | 250MG;250MG;65MG | A211695 | 001 | Feb 02, 2022 | Jan | NEWA |
|-----|----------------------|------------------|---------|-----|--------------|-----|------|

ADAPALENE

GEL;TOPICAL

ADAPALENE

| | | | | | | | |
|-----|-------------|------|---------|-----|--------------|-----|------|
| >A> | TARO PHARMS | 0.1% | A215940 | 001 | Jan 14, 2022 | Jan | NEWA |
|-----|-------------|------|---------|-----|--------------|-----|------|

ESOMEPRAZOLE MAGNESIUM

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

| | | | | | | | |
|-----|------------------|--------------|---------|-----|--------------|-----|------|
| >D> | +! DEXCEL PHARMA | EQ 20MG BASE | N214278 | 001 | Oct 20, 2020 | Jan | DISC |
| >A> | + @ | EQ 20MG BASE | N214278 | 001 | Oct 20, 2020 | Jan | DISC |

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

| | | | | | | | |
|-----|------------|------|---------|-----|--------------|-----|------|
| >A> | VKT PHARMA | 10MG | A215822 | 001 | Jan 28, 2022 | Jan | NEWA |
| >A> | | 20MG | A215822 | 002 | Jan 28, 2022 | Jan | NEWA |

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

| | | | | | | | |
|--|----------------------|-------------|---------|-----|--------------|-----|------|
| >A> | +! CHATTEM SANOFI | 60MG;120MG | N020786 | 002 | Jan 24, 2011 | Jan | CAHN |
| >A> | +! | 60MG;120MG | N020786 | 002 | Jan 24, 2011 | Jan | CAHN |
| >D> | +! SANOFI AVENTIS US | 60MG;120MG | N020786 | 002 | Jan 24, 2011 | Jan | CAHN |
| ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION | | | | | | | |
| >A> | +! CHATTEM SANOFI | 180MG;240MG | N021704 | 002 | Jan 24, 2011 | Jan | CAHN |
| >A> | +! | 180MG;240MG | N021704 | 002 | Jan 24, 2011 | Jan | CAHN |
| >D> | +! SANOFI AVENTIS US | 180MG;240MG | N021704 | 002 | Jan 24, 2011 | Jan | CAHN |

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | | |
|-----|--------------|-------------|---------|-----|--------------|-----|------|
| >A> | L PERRIGO CO | 600MG;60MG | A214407 | 001 | Feb 01, 2022 | Jan | NEWA |
| >A> | | 1.2GM;120MG | A214407 | 002 | Feb 01, 2022 | Jan | NEWA |

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

| | | | | | | | |
|--------------------|-------------------|-----------|---------|-----|--------------|-----|------|
| >A> | +! CHATTEM SANOFI | 2.5MG/5ML | N209090 | 001 | Jan 31, 2017 | Jan | CAHN |
| >D> | +! SANOFI | 2.5MG/5ML | N209090 | 001 | Jan 31, 2017 | Jan | CAHN |
| TABLET;ORAL | | | | | | | |
| XYZAL ALLERGY 24HR | | | | | | | |
| >A> | +! CHATTEM SANOFI | 5MG | N209089 | 001 | Jan 31, 2017 | Jan | CAHN |
| >D> | +! SANOFI | 5MG | N209089 | 001 | Jan 31, 2017 | Jan | CAHN |

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

| | | | | | | | |
|-----|---------------------|----|---------|-----|--------------|-----|------|
| >D> | PERRIGO | 5% | A091344 | 001 | Apr 28, 2011 | Jan | CAHN |
| >A> | PERRIGO PHARMA INTL | 5% | A091344 | 001 | Apr 28, 2011 | Jan | CAHN |

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

| | | | | | | | |
|---|----------|-------------|---------|-----|--------------|-----|------|
| >D> | +! BAYER | 220MG;120MG | N021076 | 001 | Nov 29, 1999 | Jan | DISC |
| >A> | + @ | 220MG;120MG | N021076 | 001 | Nov 29, 1999 | Jan | DISC |
| NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | | | |
| >D> | PERRIGO | 220MG;120MG | A076518 | 001 | Mar 17, 2004 | Jan | CHRS |
| >A> | ! | 220MG;120MG | A076518 | 001 | Mar 17, 2004 | Jan | CHRS |

ADDITIONS/DELETIONS FOR OTC DRUG PRODUCT LIST

POTASSIUM IODIDE

SOLUTION;ORAL
POTASSIUM IODIDE

| | | | | | | | |
|-----|----------|--------|---------|-----|--------------|-----|------|
| >D> | @ ROXANE | 1GM/ML | N018551 | 001 | Feb 19, 1982 | Jan | CRLD |
| >A> | + @ | 1GM/ML | N018551 | 001 | Feb 19, 1982 | Jan | CRLD |

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT;ORAL
ZANTAC 75

| | | | | | | | |
|-----|--------------------|--------------|---------|-----|--------------|-----|------|
| >A> | + @ CHATTEM SANOFI | EQ 75MG BASE | N020745 | 001 | Feb 26, 1998 | Jan | CAHN |
| >D> | + @ SANOFI US | EQ 75MG BASE | N020745 | 001 | Feb 26, 1998 | Jan | CAHN |

TABLET;ORAL
ZANTAC 150

| | | | | | | | |
|-----|--------------------|---------------|---------|-----|--------------|-----|------|
| >A> | + @ CHATTEM SANOFI | EQ 150MG BASE | N021698 | 001 | Aug 31, 2004 | Jan | CAHN |
| >A> | + @ | EQ 150MG BASE | N021698 | 002 | Mar 13, 2007 | Jan | CAHN |
| >D> | + @ SANOFI US | EQ 150MG BASE | N021698 | 001 | Aug 31, 2004 | Jan | CAHN |
| >D> | + @ | EQ 150MG BASE | N021698 | 002 | Mar 13, 2007 | Jan | CAHN |

ZANTAC 75

| | | | | | | | |
|-----|--------------------|--------------|---------|-----|--------------|-----|------|
| >A> | + @ CHATTEM SANOFI | EQ 75MG BASE | N020520 | 001 | Dec 19, 1995 | Jan | CAHN |
| >D> | + @ SANOFI US | EQ 75MG BASE | N020520 | 001 | Dec 19, 1995 | Jan | CAHN |

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
NASACORT ALLERGY 24 HOUR

| | | | | | | | |
|-----|----------------------|---------------|---------|-----|--------------|-----|------|
| >A> | +! CHATTEM SANOFI | 0.055MG/SPRAY | N020468 | 002 | Oct 11, 2013 | Jan | CAHN |
| >A> | +! | 0.055MG/SPRAY | N020468 | 002 | Oct 11, 2013 | Jan | CAHN |
| >D> | +! SANOFI AVENTIS US | 0.055MG/SPRAY | N020468 | 002 | Oct 11, 2013 | Jan | CAHN |

TRIAMCINOLONE ACETONIDE

| | | | | | | | |
|-----|---------------------|---------------|---------|-----|--------------|-----|------|
| >D> | PERRIGO | 0.055MG/SPRAY | A078104 | 002 | Nov 14, 2014 | Jan | CAHN |
| >A> | PERRIGO PHARMA INTL | 0.055MG/SPRAY | A078104 | 002 | Nov 14, 2014 | Jan | CAHN |

CURRENT MONTH ADDS/DELETES LIST NOTE:

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>.

The change code description:

| | |
|--------|---|
| NEWA | New drug product approval usually in the supplement month. |
| NFTG | New first time generic approval. |
| CAHN** | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMKT | Change. RX to OTC marketing status switch. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CHRS | Change. Reference Standard. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book(EOB)query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.